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Rifampicin resistance in clinical isolates of Mycobacterium tuberculosis develops through selection of 
bacterial variants harbouring mutations in the rpoB gene. These mutations infer a fitness-cost in the 
absence of antibiotic pressure, however, fitness-levels of rifampicin-resistant strains can be restored 
by compensatory mutations in rpoA and rpoC. This study was the first to investigate the 
epidemiological relevance of these compensatory mutations in clinical M. tuberculosis isolates 
collected in South Africa. Through targeted DNA sequencing, we demonstrated a strong association 
between rpoC mutations and transmission, and the rpoB S531L mutation. Our study emphasises the 
epidemiological relevance of compensatory evolution in response to the emergence of rifampicin 
resistance, and illustrates how compensatory mutations may be selected as a function of epistatic 
interactions. 
 
Recently a hypothesis has been developed which suggests that the activation of efflux systems through 
exposure to rifampicin may explain the observed spectrum of rifampicin resistance phenotypes.  To 
elucidate whether rifampicin dependent activation of efflux systems also increases energy production, 
the RNA expression profiles of candidate energy metabolism genes were investigated.  This study 
demonstrated that rifampicin exposure induced an overall increase in the expression of energy 
metabolism genes. Our findings suggest that the response to rifampicin is not universal and may 
depend on other genomic mutations. From these results we conclude that the stress response induced 
by exposure to rifampicin increases the energy production which fuels efflux activity thereby enabling 
the cell to extrude rifampicin in an energy dependent manner. This also provides a platform to explain 
the mechanism by which the newly developed drug, TMC207, increases the rate of culture conversion 
when used in combination with second-line anti-TB drugs. We propose that inhibition of ATP 
synthesis by TMC207 will deprive the efflux pumps and transporter genes of energy, which will result 
in the accumulation of second-line anti-TB drugs within the bacilli, leading to more efficient binding 
of the second-line drugs to their targets and ultimately to cell death. 
 
To identify the genetic basis governing the level of rifampicin resistance, we sequenced the genomes 
of MDR clinical isolates and in vitro generated rifampicin resistant mutants. Only minor genetic 
changes in addition to the rpoB mutation were identified in the genomes of in vitro rifampicin 
resistant mutants which displayed varying levels of resistance. This suggests that these mutants may 
either use alternative regulatory mechanisms or have acquired SNPs outside the genetic regions 
investigated in this study to modulate rifampicin resistance levels. In contrast, the genomes of clinical 
MDR isolates from the Low Copy Clade showed considerable variability in genes involved in cell 





variability in genes known to confer drug resistance and compensatory mechanisms. These results 
suggest that the structure and processes of the cell wall, as well as lipid metabolism plays a critical 
role in determining the intra-cellular concentration of rifampicin. Finally, this study illustrated the 
complexity in the physiology of M. tuberculosis resistant to rifampicin, whereby multiple mechanisms 










Rifampisien weerstandigheid in kliniese isolate van Mycobacterium tuberculosis ontwikkel deur die 
seleksie van bakteriële variante wat mutasies in die rpoB geen het.  Alhoewel hierdie mutasies lei tot 
„n afname in fiksheid van die bakterieë in die teenwoordigheid van antibiotika, kan die fiksheids 
vlakke van rifampisien weerstandige stamme herstel word deur vergoedende mutasies in rpoA en 
rpoC.  Hierdie is die eerste studie wat die epidemiologiese relevansie van hierdie vergoedende 
mutasies in kliniese M. tuberculosis isolate wat in Suid-Afrika versamel is, ondersoek.  Deur middel 
van doelgerigte DNA volgordebepaling het ons „n sterk assosiasie tussen rpoC mutasies en 
transmissie, en die rpoB S31L mutasie getoon. Hierdie studie beklemtoon die epidemiologiese 
relevansie van regstellende evolusie na aanleiding van die ontwikkeling van rifampisien 
weerstandigheid en illustreer hoe regstellende mutasies geselekteer mag word as „n funksie van 
epistatiese interaksies. 
 
„n Hipotese is onlangs ontwikkel wat voorstel dat blootstelling aan rifampisien uitvloei sisteme in die 
bakterium aktiveer, wat moontlik die waargenome spektrum van rifampisien weerstandige fenotipes 
kan verklaar. Ons het die RNA uitdrukkingsprofiele van kandidaat-energiemetabolisme gene 
ondersoek om te bepaal of rifampisien afhanklike aktivering van uitvloei sisteme ook 
energieproduksie verhoog. Hierdie studie demonstreer dat rifampisien-blootstelling „n algehele 
verhoging in die uitdrukking van energiemetabolisme gene induseer.  Ons bevindinge stel voor dat die 
reaksie van die sel op rifampisien blootstelling nie universeel is nie, en moontlik ook afhanklik is van 
ander genomiese mutasies.  Uit hierdie resultate kan ons aflei dat die stres respons wat geïnduseer 
word deur rifampisien-blootstelling energieproduksie verhoog, wat weer die uitvloei aktiwiteit 
aanvuur, en gevolglik die sel in staat stel om rifampisien op „n energie-afhanklike wyse uit te dryf.  
Dit bied ook „n basis om die meganisme te verklaar waardeur die nuwe middel, TMC207, die tempo 
van kultuuromskakeling verhoog wanneer dit saam met tweede-linie anti-TB middels gebruik word.  
Ons stel voor dat die inhibisie van ATP sintese deur TMC207 die uitvloeipompe en transporteerder 
gene van energie ontneem. Gevolglik veroorsaak dit „n ophoping van tweedelinie anti-TB middels 
binne-in die bakterium, wat geleentheid bied vir meer effektiewe binding tussen die middels en hulle 
teikens en uiteindelik seldood veroorsaak. 
 
Ons het DNA volgordes bepaal van die genome van MDR kliniese isolate en in vitro selekteerde  
rifampisienweerstandige mutante om sodoende die genetiese grondslag waarop die vlak van 
rifampisienweerstandigheid beheer word, te identifiseer. Slegs klein verskille, bo en behalwe die rpoB 
mutasie, is geïdentifiseer in die genome van in vitro rifampisien weerstandige mutante wat 





regulatoriese meganismes gebruik, of hulle het enkelnukleotied polimorfismes buite die genetiese area 
wat in hierdie studie ondersoek is, waarmee rifampisien weerstandigheid gemoduleer word.  In 
teenstelling hiermee het die genome van kliniese MDR isolate van die “Low Copy Clade” aansienlike 
variasie getoon in gene wat betrokke is by die selwand, sellulêre prosesse en lipiedmetabolisme.  
Verder het die genome van die Beijing genotipe variasie in gene getoon wat betrokke is by 
middelweerstandigheid en regstellende meganismes.  Hierdie resultate dui aan dat die struktuur en 
prosesse van die selwand, asook lipiedmetabolisme, „n kritiese rol speel in die bepaling van die 
intrasellulêre konsentrasie van rifampisien.  Opsommend, hierdie studie toon verskeie meganismes 
aan wat deur die bakterieë gebruik word om weerstandigheidsvlakke te moduleer en die kompleksiteit 
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South Africa is among the countries most severely affected by multidrug-resistant tuberculosis (MDR-
TB), which is defined by the resistance to at least the two most potent anti-TB drugs namely isoniazid 
and rifampicin. It was estimated that 9.6% of all Tuberculosis cases in South Africa in 2008 were 
MDR-TB (227). Molecular epidemiological analyses of MDR and extensively drug resistant (XDR) 
strains (i.e. MDR strains with additional resistance to any fluoroquinolone and one of the injectable 
drugs kanamycin, amikacin or capreomycin) suggest that the high incidence of drug-resistant TB in 
South Africa is largely driven by transmission (92, 149).  
 
Rifampicin is considered as one of the most important first line drugs used for the treatment of TB 
due to its strong sterilizing activity against both growing and stationary phase bacilli (89, 233). 
Rifampicin targets and subsequently inhibits RNA synthesis by binding to the β-subunit of the RNA 
polymerase (208). Mycobacterium tuberculosis (M. tuberculosis) can acquire resistance to rifampicin 
through mutations in the gene encoding its target, rpoB (152). Mutations in an 81 base pair core 
region of the rpoB gene known as the rifampicin Resistance Determining Region (RRDR) account for 
approximately 95% of rifampicin resistance detected in clinical isolates (152). The most frequently 
mutated codons being at mutations at amino acid positions 526 and 531, while mutations at 511, 516, 
518, 522 and 533 are less frequently observed in the clinical setting (152, 158). A number of studies 
have shown that the acquisition of rifampicin resistance is associated with a fitness-cost (26, 63, 120). 
Drug resistance associated fitness cost can describe as reduced growth compared to the wild type 
bacteria in the absence of drug pressure. However, in some cases clinical isolates harbouring the rpoB 
S531L mutation had no fitness-cost compared to parent wild-type isolates (26, 63). For these clinical 
isolates it was suggested that either the rpoB S531L had no fitness-cost in these particular genetic 
backgrounds, or that secondary mutations were acquired to ameliorate the initial low fitness-cost of 
the rpoB S531L mutation (63). Compensatory mutations overcome the fitness-cost associated with 
drug resistance mutations, resulting in an overall fitness level comparable to a wild-type strain in the 
absence of antibiotics (11, 62, 63). Recently, a novel set of putative compensatory polymorphisms in 
RNA polymerase genes (rpoA and rpoC) were described in rifampicin-resistant M. tuberculosis 
isolates (40). In another study, whole genome sequencing revealed that 14 out of 24 of M. 
tuberculosis clinical isolates that harboured an rpoB mutation also carried non-synonymous 
polymorphisms in rpoA or rpoC (34). Since rpoA/C is highly conserved in M. tuberculosis, it is 
therefore assumed that these polymorphisms are recently acquired. Finally, a recent study using 
genetic reconstruction and competitive growth experiments in Salmonella enteric (S. eterica) has 
shown that secondary mutations in rpoA, rpoB and rpoC were necessary and sufficient for 
compensating fitness-costs incurred by rifampicin resistance mutations (28).  The epidemiological 






The frequency and level of resistance (as expressed by the minimum inhibitory concentration (MIC) 
values) of mutations in rpoB selected by the Luria Delbrück fluctuation assay has been studied in both 
clinical and laboratory strains of M. tuberculosis (82, 120, 132).  These studies illustrated that 
mutations at amino acid positions 531 and 526 in rpoB are generally associated with higher resistant 
levels, whereas others (516, 522) generally display lower resistant levels. Important to note is that in 
some cases resistant levels were shown to be variable with mutants selected from the same progenitor 
and harbouring identical rpoB mutations (82, 120). However, for most mutations only a minimum 
MIC cut-off value was given in the respective studies and the true variability of resistance levels in in 
vitro mutants remains unclear (82, 120).  
 
Similarly, rifampicin resistance levels were also shown to be highly variable in clinical MDR and 
mono-rifampicin resistant isolates, independent of the rpoB mutation and genetic background (114). It 
was also observed that the inhibition of efflux pumps and/or transporter proteins significantly restored 
rifampicin susceptibility in these clinical isolates, while differential expression of efflux and 
transporter genes were observed after rifampicin exposure (114). These results suggested the 
importance of these efflux and transporter proteins in modulating rifampicin resistance levels. In 
addition, when investigating the proteomic response of MDR isolates after rifampicin exposure, an 
increase in the abundance of proteins essential for the production of adenosine triphospate (ATP) 
were observed (M Bester, MSc thesis, 2009). This stimulated the formation of a new hypothesis 
which proposed that increased energy production is required to drive metabolic processes (including 
efflux pumps) needed to modulate the level of rifampicin resistance (M Bester, MSc thesis, 2009).  
  
1.2. Problem Statement 
The findings described above indicate that drug resistance in M. tuberculosis is more complicated 
than previously thought. Recently the concept of one mutation conferring one resistance phenotype 
was challenged by the observation that closely related clinical and in vitro rifampicin resistant M. 
tuberculosis isolates harbouring the same rpoB mutation display varying levels of rifampicin 
resistance (114). For these isolates it was suggested that biological mechanisms in addition to the 
rpoB mutation are responsible for the varying rifampicin resistant levels.   
 
1.3. Overall Hypothesis 
The MIC of rifampicin in clinical and in vitro rifampicin resistant isolates of M. tuberculosis is 
defined by mutations other than those in the rpoB gene and that the expression of these mutations 








1.4. Overall Aim 
To identify novel mechanisms which influence the level of rifampicin resistance in clinical isolates and in 
vitro selected rifampicin resistant mutants of M. tuberculosis.  
 
1.5. Objectives 
1.5.1. To investigate the association of compensatory mutations in rpoA/C with the degree of 
antibiotic resistance in clinical isolates collected from a high incidence setting of MDR-
TB in South Africa. 
1.5.2. To investigate the expression levels of energy metabolism genes in response to 
rifampicin exposure in rifampicin resistant clinical M. tuberculosis isolates. 
1.5.3. To characterize the genotypes and phenotypes of rifampicin resistance in in vitro 
rifampicin resistant mutants selected from the Beijing and H37Rv genetic backgrounds. 
1.5.4. To identify genetic variants resulting in increased rifampicin resistance using whole 






























International guidelines recommend that drug susceptible TB should be treated with four first-line 
drugs (isoniazid, rifampicin, ethambutol, pyrazinamide) for 2 months followed by isoniazid and 
rifampicin for 4 months (224). However, non-compliance, the use of low quality drugs, 
malabsorption, and inappropriate treatment associated with diagnostic delay may lead to the 
spontaneous emergence of drug resistant TB (69, 93, 178, 228). Drug resistance has the potential to 
compromise the efficacy of treatment given the limited number of anti-TB drugs that are currently 
available. To date, four categories of drug resistance have been described for the pathogen M. 
tuberculosis (105); (i) Mono-resistance is defined as resistance to a single anti-TB drug, (ii) multiple 
resistance is defined as resistance to more than one of the first line drugs, including isoniazid or 
rifampicin, (iii) multi-drug resistant (MDR) TB is defined as M. tuberculosis strains that are resistant 
to at least isoniazid and rifampicin, whereas (iv) extensively drug resistant (XDR)-TB is defined as 
MDR-TB with additional resistance to second-line anti-TB drugs; a fluoroquinolone and any one of 
the injectable drugs i.e. kanamycin, amikacin and capreomycin (178, 235). More recently, a further 
resistance category has been proposed, namely totally drug resistant TB (TDR) which is defined as 
resistance to all first line and second-line drugs (219). However, this definition is controversial since 
not all of the second-line drug susceptibility testing methods have been standardized (101, 161).  
 
It is well established that mycobacteria can acquire resistance to both first and second line anti-TB 
drugs as a function of genetic alterations in target genes, summarized in Table 2.1. Identifying the 
mode of action (and conversely the mechanism of resistance) of an antibiotic largely depends on 
whether the antibiotic displays a broad or narrow-spectrum activity against bacterial species. In the 
case of antibiotics displaying a broad-spectrum activity, one can assume that the mechanism of action 
would be similar in most bacterial species. This is true for anti-TB drugs such as rifampicin, 
streptomycin and fluoroquinolones where the mode of action in mycobacteria were derived from 
studies done in other bacterial species such as Escherichia coli (72, 73). Therefore, similar resistance 
mechanisms in M. tuberculosis would also be assumed. In contrast, antibiotics displaying a specific 
anti-mycobacterial activity might interact with targets that are unique to mycobacteria; needs to be 
converted to an active form by enzymes unique to mycobacteria; or requires uptake systems unique to 
mycobacteria. Anti-TB drugs that belong to this category are capreomycin, ethambutol, isoniazid, 
ethionamide and pyrazinamide. The mechanism of action and resistance was identified by studying 
the effect of these drugs on the bacterial cell. Scanning electron microscopy showed that isoniazid has 
as specific effect on mycolic acid synthesis and the observation that isoniazid resistant isolates had 
attenuated catalase-peroxidase activity prompted the identification of mutations conferring resistance 
in katG (184, 225).  Similarly, the loss of pyrazinamidase activity was associated with pyrazinamide 





viomycin, which is known to inhibit protein synthesis in E. coli (90, 191). Since both antibiotics target 
the 70S ribosome, the unique activity of capreomycin against M. tuberculosis is most likely explained 
by an unique mycobacterial uptake system (38).  
 
The central dogma for drug resistance in M. tuberculosis has always involved the concept that one 
mutation results in one resistant phenotype. However, this concept has been challenged by the 
following: Firstly, it is well known that some mycobacterial species displays intrinsic resistance to 
anti-TB drugs through various cellular processes including a more adapted cell envelope, drug 
modifying enzymes and efflux mechanisms (14, 209). Secondly, it is also well documented that a 
certain percentage of drug resistant isolates do not harbour mutations in the classical resistance 
conferring genes (Table 2.2), suggesting that other resistance mechanisms exist for these isolates. 
Lastly, it has also been shown that mutations in classical drug resistance conferring genes results in 
various levels of resistance. In such instances the level of resistance, defined as the minimum 
inhibitory concentration (MIC), is the minimum concentration of an antibiotic that is required to kill 
99% of the bacterial cells in that culture (27). This differs from the critical concentration which is the 
in vitro drug concentration that is able to kill 95% of bacterial isolates which have not been previously 
exposed to the drug (61). These varying phenotypes for a given drug can be attributed by the mutation 
itself, genetic background or additional genetic variants. These observations suggests that resistant 
phenotypes are more complex than previously thought and emphasise the need for high throughput 
technology to identify novel resistance mechanisms in M. tuberculosis. 
 
This review will discuss evidence challenging the current dogma that one mutation results in one 
resistance phenotype, as well as the introduction and use of whole genome sequencing to identify 






2.2. Evidence that challenge the dogma 
 
2.2.1. Intrinsic ancient mechanisms displayed by other Mycobacteria 
Intrinsic resistance is defined as the natural resistance displayed by bacteria to an antibiotic. The 
primary mechanisms underlying intrinsic resistance in mycobacteria include i) low permeability of the 
cell wall,  ii) efflux systems, iii) the expression of antibiotic modifying and degrading enzymes, and 
iv) the expression of target-modifying enzymes (42, 43). These mechanisms may work independently 
or synergistically to protect the bacterium against the toxic effect of antibiotics (139). Such 
phenomena have been described in Mycobacterium abscessus for example, where a combination of 
low cell wall permeability and aminoglycoside-modifying enzymes confer resistance to  
aminoglycosides (138). The intrinsic mechanisms are discussed below. 
 
2.2.1.1. The Mycobacterial cell envelope 
The mycobacterial cell envelope is one of the characteristic features of mycobacteria and provides 
some level of resistance to most drugs and chemotherapeutic agents (87), since it forms the primary 
layer of protection against such extracellular compounds, including host defence factors such as 
lysozome. Additionally, it directly contributes to the virulence of mycobacteria such as those causing 
TB and leprosy (103).  The impaired permeability of mycobacterial cell wall is likely due to high 
hydrophobicity and a unique arrangement of long-chain lipophylic mycolic acids, glycopeptidolipids, 
trehalose dimycolates, arabinogalactans and peptidoglycans (30, 87). This limits the permeation of 
both hydrophobic and hydrophilic molecules. It has been shown that the deletion of a reductase 
(encoded by MSMEG4722) in M. smegmatis involved in the final step of mycolic biosynthesis 
resulted in an increased sensitivity to hydrophobic drugs such as rifampicin (decrease in MIC from 16 
µg/ml to 0.125 µg/ml), which are able to diffuse directly through the lipid membranes (23). Similarly, 
treatment of mycobacterium species with bacitracin resulted in increased cell wall permeability and a 
faster reduction of cell growth was observed when treated in combination with a hydrophobic 
rifamycin (118). This suggested that cell wall distortions caused by bacitracin resulted in enhanced 
diffusion of rifamycin into the cell (118). In M. smegmatis the rate of rifampicin influx is greatly 
reduced when compared to M. tuberculosis and M. aurum, indicating that reduced influx is a 
component of intrinsic rifampicin resistance in M. smegmatis(148).  
 
The cell wall also contains porin-like proteins which have channel-forming activities for nutrient 
uptake and the export of waste products (102). Lethal amounts of hydrophilic antibiotics are 
sometimes able to pass through these porin-channels into the mycobacterial cell; however it has been 
shown that permeability rates of these channels are 100 to 1000 fold lower than those found in 
Escherichia.coli (88). The deletion of a porin, mspA, in M. smegmatis resulted in a 16 fold increase in 
β-lactam resistance, a 10 fold increase in vancomycin resistance and a 3 fold increase in rifampicin 





susceptibility to ampicillin (2 fold decrease in MICs) (117), thereby demonstrating the inability of this 
hydrophilic compound to cross the mycobacterial cell wall and the importance of the mspA porin in 
intrinsic resistance to this β-lactam antibiotic.  Therefore, the development of drugs that could alter 
the mycobacterial cell wall permeability and the introduction thereof in the current TB treatment 
regimen could be of great importance. 
 
2.2.1.2. Antibiotic modifying/inactivating enzymes 
Acetylation 
Mycobacteria produce enzymes that inactivate antibiotics by chemical modification (209). Arylamine 
N-acetyltransferases (NATs) are enzymes that catalyse the transfer of the acetyl group from acetyl 
coenzyme A (AcCoA) to the free amino group of arylamines and hydrazines. The human N-Acetyl 
transferase (NAT2) is able to inactivate isoniazid by transferring an acetyl group to its free amino 
group forming an acetylamide (145). The M. tuberculosis Nat (nat, Rv3566c) enzyme has also been 
implicated in inactivating isoniazid since heterologous expression of M. tuberculosis Nat in M. 
smegmatis resulted in a three-fold increase in isoniazid resistance (145), while increased sensitivity to 
isoniazid was observed in a M. smegmatis ∆nat knockout mutant (146). It was also demonstrated that 
isoniazid is an excellent substrate for M. smegmatis Nat (168), and based on the high degree of 
sequence homology between the M. smegmatis Nat and M. tuberculosis Nat it was suggested that 
isoniazid might also be a good substrate for M. tuberculosis Nat. This is however controversial, since 
a recent study has demonstrated through kinetic characterization that isoniazid is a poor substrate for 
the M. tuberculosis Nat enzyme (180). Since these experiments were done in vitro, it can also be 
speculated that these findings might differ in vivo. 
 
Some M. tuberculosis clinical isolates with wildtype rpsL and rrs genes exhibit a low-level 
streptomycin resistance phenotype (MIC 25- 50 µg/ml), which is still above clinical resistance of 2 
µg/ml (58, 125, 133). This suggests that alternative mechanisms conferring streptomycin resistance 
may exist. In certain mycobacterial species (i.e. M. fortuitum, M. chelonae, M. tuberculosis and M. 
smegmatis) aminoglycoside resistance (in the absence of the known drug-resistance causing 
mutations) can be explained by the expression of acetyltransferases (4, 5, 126). Acetyltransferases 
transfer a functional group (phosphate, nucleotide or acetate) to the aminoglycoside structure, thereby 
preventing binding of the aminoglycoside to the ribosome (42, 90). Three types of transferases have 
been demonstrated: O-phosphotransferases, O-nucleotidyltransferases and N-acetyltransferases (111). 
The aac(2’)-Id gene, encoding for an N-acetyltransferase in M. fortuitum, conferred low level 
resistance to aminoglycosides when introduced into M. smegmatis mc2155 (5). Over-expression of the 
aac(2’)-Id gene resulted in higher aminoglycoside MIC values, suggesting that the intrinsic level of 
aminoglycoside resistance is determined in part by the intracellular concentration of Aac(2‟)-ld (126). 





streptomycin. No homologue of this gene is evident in other mycobacterium species (155). In 
Pseudomonas aeruginosa the aph(3’)-llb gene (encoding for an aminoglycoside-phosphotransferase) 
is under the positive control of a surrogate regulator HpaA (231). Therefore the transcriptional 
regulation of aph(3”)-lc needs to be investigated further in M. fortuitum to fully understand this 
resistance mechanism.   
 
Ribosylation 
Many fast growing mycobacteria, including M. smegmatis, M chelonae, M. flavescens, M. vaccae and 
M. parafortuitum, have been reported to be intrinsically resistant to rifampicin, in the absence of   
resistance-causing mutations in the rpoB gene (77). These mycobacteria inactivate rifampicin by 
ribosylation, whereby ADP-ribosyl transferase transfers an ADP-ribose unit to an amino acid residue 
on rifampicin (20). The enzyme responsible for this reaction is encoded by the gene arr-ms. 
Constitutive expression of arr-ms in M. smegmatis increases the rifampicin MIC to 32 µg/ml (54), 
which is significantly higher than the critical concentration (2 µg/ml) used to define rifampicin 
resistance in M. tuberculosis (208). Over-expression of recombinant arr-ms in E.coli resulted in 
increased MICs for different rifamycins to ≥ 512 μg/ml (rifabutin, rifampin, rifamycin, rifaximin) 
(20). This gene is absent from the M. tuberculosis genome thereby explaining the lower rifampicin 
MIC in this pathogen. 
 
2.2.1.3. Efflux systems 
The role of efflux pumps in intrinsic and acquired resistance is not fully understood and limited data 
exists for their role in intrinsic resistance to antibiotics currently included in the TB-regimen. It has 
been observed that inhibitors of efflux pumps mechanisms have limited effect on changing the 
rifampicin MIC in wildtype M. smegmatis, M tuberculosis and M. aurum isolates (148). This suggests 
that the genes encoding for these efflux pumps are expressed at a basal level to maintain the normal 
homeostasis within the cell (148). However, evidence suggests that the expression of efflux pump 
genes can also be induced to result in elevated levels of acquired drug resistance (113). This will be 
discussed later (section 2.2.3.7). 
 
The Major Facilitator Superfamily (MFS) efflux pump, P55, has been shown to contribute to intrinsic 
resistance to antibiotics in M. bovis (25, 181). The gene, Rv1410c, encoding its homolog in M. 
tuberculosis, forms an operon with R1411c which encodes for a lipoprotein LprG (157). It has been 
shown that this operon plays a role in the extrusion of antibiotics. In addition, it is part of the 
oxidative stress response and is required to maintain normal growth characteristics (157). Over-
expression of P55 in M. smegmatis resulted in an 8-fold increase in the MIC for streptomycin. The use 
of an energy uncoupler (Carbonyl cyanide m-chlorophenyl hydrazone) or efflux pump inhibitors 





MIC. The deletion of P55 in M. bovis BCG resulted in decreased MICs for rifampicin (0.0032 µg/ml 
to 0.0004 µg/ml), ethambutol (4 µg/ml to 2 µg/ml), and vancomycin (4 µg/ml to 0.25 µg/ml) (157), 
indicating a role for P55 in intrinsic resistance to these drugs. Interestingly, the deletion of P55 in M. 
smegmatis did not affect the rifampicin MIC, however the MICs for isoniazid and ethambutol were 
decreased 2 fold (24). This suggests that intrinsic resistance to a drug is determined by a combination 
of mechanisms and is therefore closely linked to genetic background.  
 
The Stp protein, encoded by Rv2333c in M. tuberculosis, is another pump responsible for intrinsic 
resistance in M. bovis BCG (encoded by Mb2361c). The deletion of this pump in M. bovis BCG 
resulted in a 2 and 4 fold decrease in spectinomycin and tetracycline resistance respectively (156) and 
an increase in [
3
H]tetracycline accumulation. Over-expression of Rv2333c in M. bovis BCG using a 
multicopy plasmid resulted in a 2 fold increase in spectinomycin and tetracycline resistance (156). 
 
2.2.1.4. Genetic polymorphisms of target genes 
Certain mycobacterial species such as M. abscessus, M. leprae and M. chelonea are naturally resistant 
to ethambutol due to a variant amino acid motif in the Ethambutol Region of Drug Resistance 
(ERDR) of the embB gene, resulting in an ethambutol MIC ≥ 64 µg/ml (8). Introduction of this 
variant in susceptible M. smegmatis (with an ethambutol MIC of 0.5 µg/ml) resulted in a 500-fold 
increase in the ethambutol MIC (256 µg/ml) (8). No other naturally occurring variants in target genes 
have been reported for mycobacteria.  
 
2.2.2. Classical drug resistance mutations conferring varying levels of drug resistance 
For most anti-TB antibiotics evidence suggests that classical drug resistance causing mutations confer 
varying levels of resistance for the respective antibiotic. These will be discussed below and 
summarized in Table 2.3. 
 
2.2.2.1. Isoniaizid – katG, inhA, inhA promoter mutations 
Isoniazid is one of the most important first line anti-TB drugs. On entry into the cell by passive 
diffusion, isoniazid is activated by the catalase-peroxidase enzyme encoded by katG to form 
isonicotinic acyl anions and other reactive oxygen species such as superoxide, peroxide and hydroxyl 
radicals (232). KatG is considered to be important to protect the bacteria against oxidative stress, 
specifically peroxidases produced by phagocytic cells. The metabolic products that are generated by 
the KatG-mediated isoniazid activation reacts with NAD (H) to form an isoniazid-NAD (P) adduct. 
This adduct binds to and inactivates the protein encoded by inhA which is an enoyl-acyl carrier 
protein (ACP) reductase, involved in mycolic acid synthesis (159). Inactivation of inhA therefore 
leads to the inhibition of cell wall synthesis and cell death. Certain mutations in the katG gene confer 
high level resistance to isoniazid (MIC > 5 µg/ml) and occur in 50-95% of all isoniazid resistant 





target of isoniazid, will affect the structure of InhA, resulting in isoniazid resistance (152). These 
structural mutations are rarely seen in clinical isolates and generally confer low level isoniazid 
resistance (MIC < 0.5 µg/ml) (154, 178, 222). The promoter regulating the expression of inhA has 
been identified to be positioned upstream from the mabA/inhA operon (17). Various mutations in this 
promoter region (-15 C to T, -17 G to T and -8 T to C) (15) lead to the over-expression of inhA, 
resulting in an increase in the concentration of InhA which partially overcomes the toxic metabolic by 
products generated by KatG (17, 104, 116). These inhA mutations are associated with low-level INH 
resistance (MIC 0.2 -1 µg/ml) (75). 
 
2.2.2.2. Rifampicin – rpoB mutations 
Since nucleotide substitutions in rpoB result in a decreased binding affinity of RNA polymerase for 
rifampicin, the level of rifampicin resistance is dependent on the position of the mutation in the rpoB 
gene (82). Although most rpoB mutations cause resistance above the critical concentration of 2 g/ml, 
the MIC for rifampicin has been reported to range from 32 to 256 µg/ml on 7H10 solid media (Table 
2.3) (82). In clinical isolates, mutations at codon Ser531 and His526 account for more than 75% of 
rifampicin resistance and these mutations are associated with high-level rifampicin resistance (MIC > 
32 µg/ml). However, mutations found at positions 511, 516, 518 and 522 are associated with lower-
level resistance (233). Some reports have described rifampicin MICs in liquid media of 1-2 µg/ml as 
“lower-level resistance”, where the critical concentration is defined at 1 µg/ml (74, 216, 217) . It is 
suggested that a higher dose of treatment might still be feasible for isolates with MICs up to 1 µg/ml 
(216).  
 
2.2.2.3. Pyrazinamide – pncA mutations 
Pyrazinamide is an important first-line drug for the treatment of TB as it appears to be important for 
the killing of latent M. tuberculosis (81). Pyrazinamide needs to be hydrolised by pyrazinamidases to 
its active form, pyrazinoic acid (98, 177). Pyrazinamidases are expressed constitutively in 
pyrazinamide susceptible M. tuberculosis isolates. Mutations in the gene, pncA, encoding for 
pyrazinamidases resulted in decreased pyrazinamidases activity, thereby causing resistance to 
pyrazinamide. These mutations are scattered throughout the pncA gene, with some degree of 
clustering in regions that contain the active (D8, K96, A134 and C138) and metal-binding (D49, H51 
and H71) sites of pyrazinamidases (51). Mutations in the metal-binding site (D49N, H51R) results in 
the lowest enzymatic activity and are associated with the highest pyrazinamide resistance (MIC of 
400 µg/ml and > 800 µg/ml respectively), where mutations near the active site (D12A, D12G, F49L) 
showed pyrazinamide resistance levels of 400 µg/ml(177). Even though this study showed that 
resistance levels are negatively correlated with enzymatic activity, it was also demonstrated that only 





than low pyrazinamidase activity should occur frequently and are associated with pncA mutations 
(177). 
 
2.2.2.4. Ethambutol – embB mutations 
Amino acid substitutions at embB306 are associated with ethambutol resistance, however the change 
in level of resistance is determined by the nature of the amino acid substitution at that position (188). 
For example, it has been shown that Met306Leu and Met306Val substitutions are associated with high 
level ethambutol resistance (40 µg/ml), while Met306Ile substitutions are associated with low level 
ethambutol resistance (20 µg/ml) (86, 188), where the critical concentration for ethambutol is defined 
at 5 µg/ml (67). Mutations at codon 306 in in vitro selected EMB resistant mutants conferred EMB 
resistance with a MIC of 8 µg/ml, which is significantly lower than what is found in clinical isolates. 
This suggests that additional mutations at currently unknown loci contribute towards the high level 
EMB resistance (162).  
 
2.2.2.5. Streptomycin – rpsL, rrs mutations 
Streptomycin inhibits protein synthesis by binding to the 30S subunit of bacterial ribosome, with the 
site of action at the ribosomal protein S12 and 16S rRNA (233). Thus mutations in rpsL, encoding for 
the S12 protein, and rrs, encoding for 16S rRNA, confers resistance to streptomycin (58). Mutations 
in the rpsL gene are associated with high level streptomycin resistance, with Lys43Arg mutations 
resulting in an MIC >1000 µg/ml, while Lys88Arg mutations result in MICs ranging from 250 to > 
1000 µg/ml (125, 140). Mutations in the rrs gene are associated with intermediate levels of 
streptomycin resistance (MIC 50 – 500 µg/ml) (125). 
 
2.2.2.6. Ofloxacin – gyrA mutations 
Ofloxacin is a fluoroquinolone used as a second-line drug for the treatment of MDR-TB. In M. 
tuberculosis it targets and inactivates a type II DNA polymerase (DNA gyrase) thereby introducing 
negative supercoils in the circular DNA molecule. Mutations in the genes encoding for the DNA 
gyrase, gyrA and gyrB, are responsible for conferring resistance to fluoroquinolone (152). Asp94Gly 
substitutions in the gyrA gene are associated with high level ofloxacin resistance (MIC >20 µg/ml) 
(94, 202), whereas Ala90Val and Ser91Pro substitutions are associated with a lower level of ofloxacin 
resistance (MIC ≤ 6 µg/ml) (36, 183). It is speculated that the Asp94Gly mutation has the greatest 
influence on the binding constant between the DNA gyrase and the fluoroquinolone, resulting in a 
higher MIC. In contrast, isolates harbouring Asp94Gly substitutions displayed lower level 
moxifloxacin resistance (MIC 1-2 µg/ml), but still considered as resistant since the critical 
concentration of moxifloxacin is 0.25 µg/ml (119, 183). Since these susceptibility levels are below the 
peak serum concentration (4 µg/ml) it is suggested that moxifloxacin can still be used for the 






2.2.3. Non-classical mutations modulating the levels of drug resistance 
There is cumulative evidence that other genes (other than the classical drug resistance conferring 
genes) have the ability of modulating the levels of resistance. These mechanisms will be discussed 
below and summarized in Table 2.3. 
 
2.2.3.1. Isoniazid – furA mutations 
As discussed above, isoniazid is a prodrug which is activated by KatG. Therefore, one can argue that 
the MIC for isoniazid is defined by the rate at which isoniazid is activated by KatG, rather than the 
interaction of its activated metabolic products with downstream cellular processes (150). KatG, 
catalase-peroxidase enzyme, is considered to be an important protective mechanism against oxidative 
stress, specifically peroxidases produced by phagocytic cells (106). Accordingly, the isoniazid MIC is 
determined largely by the rate of expression of katG and the functionality of the encoded KatG. In 
contrast to E. coli, expression of katG in members of the M. tuberculosis complex (M. tuberculosis, 
M. bovis, M. africanum and M. microti) is not regulated by the LysR transcriptional activator,oxyR 
(194, 195), since oxyR is deleted in these members. Thus, the regulation of katG is thought to occur 
through alternative regulatory proteins present in the proteome of these mycobacteria (47, 48, 179). 
Previous studies done in non-mycobacterial species have suggested that expression of oxidative stress 
genes is coupled to iron metabolism via the ferric uptake regulator, Fur (229). This prompted the 
investigation of the relationship between the fur orthologues in M. tuberculosis and katG expression. 
Whole genome sequencing of M. tuberculosis revealed that a fur-like gene, furA, is positioned 40 bp 
upstream of katG and that both genes are co-transcribed (48, 143, 150). Subsequently it has been 
shown that the katG locus is genetically linked to the furA gene in all mycobacteria (229). This 
suggested that FurA might act as a transcriptional regulator of a subset of oxidative stress response 
genes (48, 143). Further investigation of this region revealed that katG is transcribed from two 
promoters (127). One promoter controls transcripts produced during early infection and contains both 
the furA and katG, whereas the second transcript contains only katG and is produced during extended 
growth in macrophages. It is suggested that due to the presence of only one catalase in M. 
tuberculosis, the bacteria has adapted to express katG from two promoters depending on the 
environmental inputs and physiological demands (127). Deletion of furA results in an increase in katG 
expression and hypersensitivity to isoniazid (decreased MIC) (229), suggesting that FurA acts as a 
repressor of katG expression (150). This is consistent with the observation that FurA negatively 
regulates its own expression by binding to a region upstream of furA (163). To date, only two furA 
mutant clinical isolates have been reported (150). Since these strains also have mutations in the katG 
gene, the direct effect of these furA mutations on the level of isoniazid resistance could not be 
determined, although it is tempting to speculate that the furA mutations may modulate the level of 
isoniazid resistance by altering katG expression. Recently, mutations were identified in clinical M. 





associated isoniazid resistance (13). It was shown that the introduction of these mutations (-7 G to A, -
10 A to C) in isogenic strains resulted in decreased expression of katG and increased isoniazid 
resistance (MIC 0.2 µg/ml) (12). 
 
A second regulatory mechanism for katG has been proposed in M. tuberculosis involving a LysR-type 
regulator, OxyS (49). It has been shown that OxyS is an oxidative stress response regulator in M. 
tuberculosis that binds to the immediate region upstream of katG in the terminal region of furA (109). 
Over expression of oxyS in M. smegmatis resulted in a two fold increase in katG expression, while no 
significant change was observed in the expression of furA (109). These results suggested that katG is 
negatively regulated by OxyS. Over expression or reduction in the expression of OxyS did however 
not change susceptibility to isoniazid (49). 
 
2.2.3.2. Streptomycin – gidB mutations 
Various studies have reported the association of mutations in gidB (a putative 16S rRNA) in M. 
tuberculosis clinical isolates and low level streptomycin resistance (226). However, in various reports 
mutations in gidB were present in both streptomycin resistant and susceptible isolates, questioning the 
association with streptomycin resistance (140). Recently, the deletion of this gene resulted in a 16 fold 
increase in the streptomycin MIC (226). Complementation of the ΔgidB mutant with a wild type copy 
of gidB resulted in the restoration of streptomycin susceptibility. Additionally, it was shown that 
clinical isolates harbouring a gidB mutation had on average a 4 fold higher streptomycin MIC than 
those without a gidB mutation. However, part of the population of gidB mutation-containing isolates 
had a MIC of less than or equal to the critical concentration of streptomycin, and were thus classified 
as streptomycin sensitive. Pharmacodynamic analysis and Monte Carlo simulation of the streptomycin 
resistant gidB mutation-containing isolates suggested that these isolates will respond poorly with 
streptomycin treatment, even though these isolates demonstrated only low level streptomycin 
resistance. Drug susceptibility testing in 7H9 liquid media and LJ resulted in discordant results. This 
raised the question whether the critical concentration is set too low for LJ testing, resulting in isolates 
being scored as sensitive, while they are in fact clinically resistant (226). 
 
2.2.3.3. Ethambutol – embR mutations 
The level of ethambutol resistance may be influenced by the level of expression of the embCAB-
operon, encoding for the drug target. This operon is present in all mycobacterial species; however, in 
M. avium the emb gene cluster contains only the embAB genes with an additional gene, embR, 
immediately upstream of the embAB genes (21, 153). EmbR encodes for a putative transcriptional 
activator belonging to the OmpR-like family (9) and is a multi-domain protein that possesses a DNA 
binding winged helix-turn-helix domain, a bacterial transcription activation domain and a forkhead-





is located 2 MB from the embCAB locus, and is hypothesized to modulate the level of embCAB 
expression and thereby arbinosyltransferase activity (39, 153).      
 
The Ser/Thr protein kinase, PnkH is another protein involved in the transcriptional regulation of the 
embCAB operon (129). PnkH is a sensory protein which becomes autophosphorylated in response to 
external stimuli thereby increasing the protein kinase activity (129). In turn, PnkH phosphorylates the 
C-terminal FHA domain of EmbR. FHA domains are capable of mediating protein-protein 
interactions through P-Thr (phosphothreonine) recognition and often participate in STPK-dependant 
signal-transduction pathways (53). The phosphorylation of EmbR enhances the binding activity 
towards the promoter regions of embCAB in M. tuberculosis (129, 176). Since ethambutol resistance 
depends on the abundance of EmbB and EmbA in the cell, increased expression of embCAB through 
increased activation by the PnkH-EmbR pair is predicted to increase EMB resistance (21, 176). This 
is supported by the observation that expression of PknH but not pknH harbouring the K45M mutation 
(this mutation in the ATP binding site abrogates the kinase activity of PknH) in M. smegmatis 
increased expression of embCAB (176). The ethambutol MICs of the M. smegmatis PknH K45M 
mutant increased threefold (0.75 µg/ml) when compared with the M. smegmatis strains harbouring the 
wild type kinase (0.25µg/ml). Conversely, mutations in the FHA domain of EmbR have been 
associated with ethambutol resistance (153). Recently the embR gene of 44 resistant isolates were 
screened and mutations were observed in 16/44 (36%) isolates at 23 different codons (190). The effect 
of these mutations on the level of ethambutol resistance, however, was not determined. 
 
Recently a protein, EmbR2 (130), identified in M. tuberculosis CDC1551 was shown to inhibit the 
PknH-dependant phophorylation of EmbR. MT3428, the gene encoding for EmbR2, was annotated as 
a putative transcriptional regulator and shown to be absent from M. tuberculosis strain H37Rv. The 
gene is also present in other mycobacterial genomes such as M. bovis and M. bovis BCG. EmbR2 and 
EmbR share 55% sequence identity over 381 residues. In contrast to embR, which is genetically 
linked to pknH (39, 130), embR2 is found to be genetically distant to pknH and is not phophorylated 
by PknH. Increasing concentrations of EmbR2, inhibited the phosphorylation of EmbR in a dose-
dependent manner (130).  
 
2.2.3.4. Ethionamide – ethA, ethR mutations 
Ethionamide is a pro-drug that is activated by EthA (a FAD-containing monooxygenase enzyme), to 
generate metabolic by-products which exert a toxic effect upon the synthesis of the mycolic acid 
constituents of the mycobacterial cell wall (19, 45). The expression of ethA is negatively regulated by 
its neighbouring gene, ethR (19, 45). EthR is a member of the TetR/CamR family of transcriptional 
regulators which binds cooperatively as a homo-octamer to the ethA operator, 5 to 16 nucleotides 





ethA which in turn determines the level the intrinsic resistance to ethionamide (60). This is supported 
by the observation that over expression of ethR leads to repression of expression of ethA and to an 
increase in the MIC of ethionamide from 15 µg/ml to 250 µg/ml in M. smegmatis (19, 45). 
Conversely, it is suggested that conditions leading to the down-regulation of ethR expression or a 
mutation in the ethR gene increases ethionamide susceptibility (lowering the MIC) (19). The deletion 
of ethR in M. bovis BCG increased the sensitivity to ethionamide from an MIC of 2µg/ml to an MIC < 
0.6 µg/ml (19). Similarly, the addition of benzylacetone, which binds to EthR thereby prevented its 
binding to the ethA operator, appeared to cause a potent bacteriostatic effect when co-administrated 
with ethionamide (60). 
 
2.2.3.5. Amikacin – eis promoter mutations 
It is known that certain mutations in the 16S rRNA gene, rrs, can cause high-level resistance to 
kanamycin with MICs exceeding 80µg/ml (121). The rrs1401A/G mutation can also confer cross 
resistance to other second-line drugs such as amikacin and capreomycin (121). However, up to 80% 
of kanamycin-resistant clinical isolates which display low-level resistance to kanamycin, do not have 
mutations in the rrs gene and do not exhibit cross-resistance (100, 204). Recently, a previously 
unidentified mechanism of kanamycin resistance was described which resulted as a consequence of 
point mutations in the promoter region of, eis, the enhanced intracellular gene (230). Eis shares 
sequence homology and secondary structural characteristics with the GCN5-related N-acetyltranferase 
(GNAT) superfamily of acetyltransferases, which includes the aminoglycoside N-acetyltransferase 
(166, 220). Expression analysis revealed that isolates harbouring these promoter mutations have 180 
fold higher transcript levels than the wild type H37Rv laboratory strain, and introduction of this 
mutation in H37Rv increased its resistance to kanamycin to between 20-25 µg/ml. Eis acetylates 
kanamycin at a rate 3.3 fold higher than that of amikacin, which explains the observed absence of 
cross-resistance to kanamycin and amikacin in isolates harbouring eis mutations. Therefore, testing of 
suspect drug resistant cases can be important as isolates harbouring eis promoter mutations and 
resistant to kanamycin can still be treated with amikacin.  
 
2.2.3.6. Ciprofloxacin – lfrA, lfrR 
The lfrA gene in M. smegmatis encodes a transporter which confers low-level resistance to 
fluoroquinolone ciprofloxacin when over expressed (by cloning lfrA into a multicopy vector) (110, 
206). Conversely, the disruption of lfrA resulted in a 2 fold decrease of the MICs for ciprofloxacin 
(110, 167). lfrR, an open reading frame (570 bp), upstream of the lfrA gene shares homology with 
several TetR transcriptional proteins (108). TetR transcriptional regulators are characterized by a 
conserved DNA binding domain (helix-turn-helix at the N-terminal) and a ligand binding domain (C-
terminal region). Binding of an inducing ligand to the C-terminal region results in conformational 
changes in the N-terminal region, reducing its affinity to its target promoter DNA (78). Transcript 





base pairs upstream from lfrR (31). LfrR represses lfrA expression by binding directly to the promoter 
region of lfrR-lfrA (31). Various LfrA substrates (Acriflavine and Ethidiumbromide) were found to 
up-regulate the expression of the transporter by specifically promoting the dissociation of the 
repressor-operator complex (31). Addition of excess amount of acriflavine (2X MIC) abolished the 
binding of LfrR to the 43bp DNA region, suggesting that acriflavine acts as a ligand inducer for LfrR. 
Although ciprofloxacin acts as a substrate of lfrA it showed no interaction with LfrR, demonstrating 
that not all substrates of lfrA act as inducers. Since there are no known homologs of lfrA in M. 
tuberculosis it is speculated that the regulation of other efflux pumps may be involved in resistance to 
fluoroquinolones in M. tuberculosis (43, 44). A two to eight fold reduction in ofloxacin MICs were 
observed in ofloxacin resistant isolates (harbouring an gyrA mutation) when treated with efflux pump 
inhibitors cyanide m-chlorophenyl hydrazone (CCCP), 2,4-dinitrophenol (DNP), and verapamil (56, 
182).  
 
2.2.3.7. Unknown regulatory mutations leading to induced resistance 
Prolonged exposure of fully susceptible and rifampicin-mono resistant clinical M. tuberculosis 
isolates to sub-inhibitory concentrations of isoniazid (0.1 µg/ml) resulted in increased isoniazid MICs 
(exceeding 64 µg/ml), which is considered high-level resistance (115). The increased resistance 
phenotype could also be reduced by means of efflux pump inhibitors (thioridazine, chlorpromazine 
and verapamil). Increased gene expression of efflux systems (mmpl7, Rv1258c, P55, mmr and 
Rv2459) correlated well with enhanced real-time efflux of a common efflux substrate, ethidium 
bromide. Further exposure of these isolates to isoniazid resulted in the selection of mutations and 
deletions in katG along with sustained increased efflux activity. It was therefore suggested that efflux 
systems play a role in the development of isoniazid resistance by allowing a subpopulation of the 
bacterial cells to survive during exposure to sub-inhibitory concentrations of isoniazid. During this 
period, mutations conferring high-level and stable isoniazid resistance can be selected for. Even 
though a significant increase in the expression of efflux genes were observed, their activity seemed 
promiscuous as an association between the extrusion of isoniazid and a specific gene could not be 
made (115). Inconsistent up-regulation of efflux pump and transporter genes following rifampicin 
exposure was also observed among closely related MDR M. tuberculosis isolates (114). In that study 
it was also shown that that the exposure of rifampicin mono-resistant and MDR isolates to 2 µg/ml 
rifampicin for 7 days induced a 10 fold increase in the ofloxacin MIC (114). Even though the 
regulatory mechanisms responsible for the antibiotic-induced efflux-mediated response described 
above are unknown, several other studies have shown the up regulation of efflux and transporters 







2.3. The use of whole genome sequencing in identifying novel drug resistance causing 
mechanisms 
Several reviews have described expanding applications of next generation sequencing techniques in 
microbial research  (10, 70, 80). Whole genome sequencing of the M. tuberculosis laboratory strain, 
H37Rv, was a revolutionary turning point for modern mycobacterial research and provided important 
insights into the biology of the species (39). With the development of next generation sequencing 
technologies, whole genome sequencing of additional M. tuberculosis laboratory and clinical isolates 
have allowed for large scale comparative and evolutionary studies (40, 124, 174). 
 
In the pre-seqeuncing era, M. tuberculosis clinical strains have always been described as 
“monomorphic” with low sequence variation between strains (3). M. tuberculosis isolates from the 
same strain cluster (as characterized by IS6110 RFLP) were considered as identical with little 
genomic diversity (218). Whole genome sequencing has however shown that there is high genomic 
diversity between seemingly closely related M. tuberculosis isolates. Comparative whole genome 
sequencing of two Beijing isolates with identical DNA fingerprints, identified 160 SNPs and one 
deletion differentiating the two isolates (142). Additionally, re-sequencing and comparative genomic 
analysis of the laboratory strains H37Rv and H37Ra identified 30 SNPs and 74 insertion-deletion 
events accumulated during low number of passages which possibly resulted in attenuation and gain of 
resistance to lysis (234). Re-sequencing of six H37Rv laboratory strains collected from multiple 
laboratories also revealed several evolutionary events occurring in the in vitro environment (85). 
These two studies demonstrated how the genomes of M. tuberculosis isolates continuously evolve, 
even in a controlled environment.  
 
The mutation rate accompanied with in vivo acquired drug resistance within single patient sputum 
samples or within patient-to-patient transmission events, however, appears to be very low. Re-
sequencing of drug sensitive isolates collected from a five-patient transmission chain revealed that 
only one SNP occurred over six years and three transmissions, while only four mutational events (2 
SNPs a tandem repeat change and IS6110 transposition change) occurred sequentially in a single 
patient (173). In a separate study, only two point mutations (katG S315T and rpoB D516Y) were 
identified in non-repetitive regions between serial sputum isolates collected from a single patient over 
a period of 12 months (171). These sputum isolates evolved from fully sensitive to MDR over a 
period of 12 months. The two points mutations identified are known to confer isoniazid and 
rifampicin resistance, and therefore the lack of any additional mutations suggested a low mutation rate 
per generation in the acquisition of MDR (171). In contrast, whole genome sequencing of MDR and 
XDR outbreak strains from HIV positive patients from KwaZulu Natal, South Africa, identified 22 
SNPs which were unique to the XDR genome or shared by only the MDR and XDR genomes (134).  





12 were found to be associated with a drug resistance phenotype or compensatory mechanism and 
found to be unique to the KwaZulu Natal clade. Investigation of the flanking regions of these SNPs in 
other M. tuberculosis strains revealed that only one SNP were monophyletic, suggesting that these 
SNPs were markers for strain-phylogeny. It is thought that a large degree of genetic diversity 
observed between lineages (or clades) is likely to have a functional meaning (76). This is also 
supported by the observation that closely related Streptococcus M3 strains with seemingly modest 
genetic changes have significant different transcriptomes (22).  
 
While whole genome sequencing has proven to be a valuable tool for the identification of mutations 
conferring resistance for new anti-TB drugs when sequencing is done from in vitro selected mutants 
(14, 66, 205), most studies using whole genome sequencing as an investigative tool have highlighted 
certain limitations in the current technology (59). Firstly, polymorphisms in transposable elements, 
repetitive regions (such as the PE-PPE genes), gene duplications and genetic regions absent in the 
reference genome are difficult to detect by current next-generation sequencing technologies. 
Secondly, comparative genomic analysis has limited discriminating power to distinguish adaptive 
mutations from neutral or compensatory. Lastly, the whole genome sequencing studies mentioned 
above were done from a mixture of bacterial cells which might include sub-populations with varying 
genotypes and phenotypes. Given the low sensitivity and coverage depth of some of these studies‟ 
sequencing strategies, SNPs acquired in adapting sub-populations will be mistaken for sequencing 
errors. A recent study has investigated heterozygous mapping results by using statistical approaches to 
distinguish sequencing errors from real polymorphisms (201). This study was able to show the 
fixation of adaptive mutations in evolving M. tuberculosis sputum populations. Another option to 
identify heterogeneity would be to sequence from single colony forming units, or to increase the 
sequencing coverage to accurately detect low-frequency variants. Thus the success of future next 
generation experiments will depend on the careful planning of the study design to increase the 
identification of essential variants in adapting bacterial populations.  
 
2.4. Concluding remarks 
It was generally thought that specific mutations in target genes result in specific drug resistance 
levels. However, recent reports show that drug resistance is more complex than the concept that a 
single mutation in a target gene is the sole mechanism modulating resistance against a given 
compound. The multi-faceted aspect of the mechanisms that influence the intracellular drug 
concentration is illustrated by the concept of varying levels of drug resistance for a single mutation in 
one target gene. Even though whole genome sequencing has also proven to be a valuable tool for the 
identification of mutations conferring resistance for new anti-TB drugs, the identification of variants 
essential for the evolution of drug resistance is hindered by several limiting factors presented by the 





functional relevance of these identified variants is still a daunting task and very few studies have 
made an association between genetic variants and phenotype. Finally, this review highlights the 
importance of an anti-TB regimen which targets a broad range of cellular mechanisms. New drugs 
complementing the efficacy of existing drugs should be included in regimens to shorten and improve 
treatment outcomes. Additionally, the inclusion of existing drugs currently not used in the TB 






Table 2.1: Summary of genes associated with drug resistance in M. tuberculosis. 











Isoniazid (INH) InhA katG Catalase peroxidase 
(153, 154) 
 
ahpC Alkyl hydroperoxide 
inhA fatty acid enoyl acyl carrier 
protein reductase A 
kasA β-ketoacyl-ACP 
Ndh NADH dehydrogenease 
Rifampicin (RIF) β subunit RNA 
polymerase 
rpoB β subunit RNA polymerase 
(35, 208) 
Pyrazinamide (PZA) No specific target pncA Pyrazinomidase (175) 

























Streptomycin (STR) 16S rRNA 
ribosomal subunits 
rpsL 16S rRNA ribosomal subunits 
(7, 58, 121, 
122) 
Capreomycin (CAP) rrs 
Kanamycin (KAN) tlyA  
Amikacin  (AMI) 
Ethionamide (ETH) InhA inhA fatty acid enoyl acyl carrier 
protein reductase A 
(55, 131) 
 
ethA flavin monooxygenase 
ethR Transcriptional regulator 









Table 2.2: Percentage of drug resistance clinical M. tuberculosis isolates with no classical 
mutations 
Drug 
Percentage of drug resistance 
clinical M. tuberculosis isolates 
with no classical mutation 
Reference 
Isoniazid 9-30 (32, 152, 154) 
Rifampicin 2-5 (32, 151, 210) 
Ethambutol 21 (32) 
Pyrazinamide 15 (32, 193) 
Ciprofloxacin/ofloxacin 8 (32) 
Kanamycin 17-20 (32, 65) 
Amikycin 10-20 (32, 65) 
Capreomycin 20-28 (32, 65) 
 
Table 2.3: Classical and non-classical mutations modulating the level of resistance 
Drug  Locus Mutation MIC Reference 
Isoniazid 
Classical 
katG  High level > 5 µg/ml (1, 75, 152) 
InhA  Low level < 0.5µg/ml (154) 
InhA promoter 
-15 C to T, 
 -17 G to T, 
-8 T to C 




-7 G to A, 
-10 A to C 
Increased resistance 
(MIC 0.2 µg/ml) 
(12, 143, 150, 
229) 
Rifampicin Classical rpoB 
Ser531Leu 
>64 µg/ml (219) 
>512 µg/ml (41) 
> 32* µg/ml (120) 
≥ 32 - ≥ 256*µg/ml (82) 
10-170 µg/ml (114) 
His526Tyr 
10-64 µg/ml (189) 
>512µg/ml (41) 
> 32µg/ml * (120) 





Leu511Pro Low level (233) 
Asp516Val Low level (233) 
Ser522Leu 
8-16 µg/ml * (82) 
>16 µg/ml * (120) 
Pyrazinamide Classical pncA 
Asp49Asn, 
His51Arg 




> 400 µg/ml (177) 
Ethambutol 
Classical  embB 
Met306Leu, 
Met306Val 
High level 40 µg/ml (67, 86) 





Unknown Unknown (9, 129, 130) 
Streptomycin 
Classical 
rpsL Lys43Arg > 1000 µg/ml (140, 153) 
 Lys88Arg 250 - >1000 µg/ml (153) 
rrs  50 -500 µg/ml (125) 
Non-Classical gidB  Low level ≤ 16 µg/ml (226) 
Amikacin 




Unknown (166, 230) 
Ofloxacin Classical gyrA 
Asp94Gly > 20 µg/ml (94, 183, 202) 
Ala90Val and 
Ser91Pro 
Low level  




Non-classical lfrA-lfrR Unknown Unknown 
(108, 110, 
167, 206) 
Ethionamide Non-Classical EthR Unknown Unknown (19, 60) 
Legend to Table 2.3  


























3.1. Epidemiological relevance of compensatory mutations in rpoA/C 
3.1.1.  M. tuberculosis strain selection 
Sputum specimens from Tuberculosis (TB) suspect cases were submitted to the National Health 
Laboratory Services (NHLS) in Green Point, South Africa for routine culture phenotypic drug 
susceptibility testing (DST) as described previously (197). Tuberculosis cases confirmed by the NHLS 
were subsequently subjected to genotypic testing by targeted gene sequencing in rpoB, katG, inhA, 
inhA promoter region, embB, pncA, gyrA and rrs (112, 197, 221), Spoligotyping (95, 198, 199) and 
IS6110 restriction fragment length polymorphism (RFLP) DNA fingerprinting (215). All specimens 
were stored at the Department of Biomedical Sciences, Stellenbosch University to form a longitudinal 
culture bank (112, 197, 221). Well characterized M. tuberculosis isolates were selected from  the 
longitudinal culture bank and included both sensitive (n=67) and drug-resistant (n=298) M. 
tuberculosis isolates collected between 2000-2010 from patients resident in the Western Cape, South 
Africa, (37, 197). This isolate panel represented a mixture of different drug resistant phenotypes 
including: isoniazid mono-resistant, rifampicin mono-resistant, MDR sensu stricto (excluding pre-
XDR and XDR cases), pre-XDR and XDR. The genetic population structure of this sample set is 
summarized in Table 3.1. Isolates belonging to the Beijing family were further sub-characterised into 
“typical” and “atypical” Beijing isolates by PCR (196). Isolates belonging to the atypical Beijing 
strain family were previously termed the R86 genotype (84). Clustered isolates were defined as having 
identical RFLP patterns while non-clustered patterns were unique and not detected in any other isolate 
of the full collection. 
 
Table 3.1: Population structure of clinical isolates selected in the Western Cape, South Africa 








5 1 0 1 12 14 31 64 
BEIJING Unknown 0 1 0 8 3 1 0 13 
LCC All 29 5 7 2 21 4 9 77 
LAM All 11 8 1 16 20 9 4 69 
T All 0 9 0 15 5 6 2 37 
Unknown All 1 3 0 3 11 4 0 22 
F28 All 0 0 0 0 2 0 0 2 
HAARLEM All 0 0 0 0 0 0 2 2 
CAS All 0 0 0 0 0 1 0 1 
EAI All 0 0 0 1 0 0 0 1 
F26 All 0 0 0 0 1 0 0 1 
Total  67 35 9 55 101 49 49 365 
Legend to Table 3.1: 
DS: Drug susceptible; INH: Isoniazid mono-resistant; MULTI: Rifampicin or isoniazid mono-resistant + other 
resistance to at least one other drug (not MDR); RIF: Rifampicin mono-resistant; MDR: Multi drug resistant 
XDR: Extensive drug resistant; LCC: Low Copy Clade lineage; LAM: Latin American Mediterranean lineage  





3.1.2.  Target gene sequencing 
3.1.2.1. Preparation of cultures for the preparation of DNA templates for PCR amplification 
A 500 µl aliquot of the BACTEC MGIT 960 culture of each isolate was boiled in a 1.5 ml Eppendorf 
tube (Merck, New Jersey, USA) for 20 minutes at 100°C to release crude DNA templates. 
 
3.1.2.2. Primer design 
Oligonucleotide primers (Table 3.2) were designed using Primer3 software (160) using the whole 
genome sequence of the M. tuberculosis H37Rv reference strain 
(http://genolist.pasteur.fr/TubercuList). Primers spanning the entire rpoA locus (Rv3457c) (-15 bp 
upstream, + 20bp downstream of Rv3457c), as well as the region encoding the RpoA-RpoC 
interaction site in rpoC (Rv0668, bp  735-1680) (40) were designed.  
 
Table 3.2: Oligonucleotide primers used in this study for the detection of nucleotide 
substitutions in rpoA and rpoC 





Forward 5‟ gcattccagtcgattccatc 3‟ 
676 
60.43 
Reverse 5‟ ccaagatcgccttctgatgt 3‟ 60.22 
rpoA2 Forward 5‟ ggacgtcgaaaggaagaaga 3‟ 
639 
59.41 
Reverse 5‟ gtctccacgtccaggatcag 3‟ 60.68 
rpoC 
Forward 5„ cgaaaacctctaccgcgaac 3‟ 
992 
62.02 
Reverse 5‟ gcgacaggatgttgttggag 3‟ 61.67 
Legend to Table 3.2:  
* DNA melting temperature 
 
3.1.2.3. Polymerase Chain Reaction (PCR) 
PCR reactions were performed under the following thermocycling conditions: The PCR reactions 
were executed in 25 µl reaction volumes. The PCR master-mix consisted of 1x Q-solution, 1x 
reaction buffer, 2mM MgCl2, 200µM of each deoxyribonucleotide triphospate (dNTP), 50 µM 
Forward primer, 50µM Reverse primer, 1.25 U Hotstar Taq polymerase, 1.25 µl of the crude DNA 
template, and H2O to make up a final volume of 25 µl. The reaction mixtures were heated in the 
thermal cycler (GeneAmp PCR System 2400, Applied Biosystems, Foster City, CA, USA) at the 
following conditions: an initial denaturing step at 95ºC for 15 minutes, followed by 35 cycles of a 
denaturing step at 94ºC for 1 minute, an annealing step at Tm (62ºC) for 1 minute, an extension step at 
72ºC for 2 minutes, and a final extension step at 72ºC for 15 minutes. All PCR experiments included a 







3.1.2.4. Gel electrophoresis 
A 1.5% Agarose gel was prepared by dissolving 1.5 g Agarose in 100 ml 1x-TBE (pH 8.3) buffer by 
boiling. Once the mixture had cooled, 5 µl ethidiumbromide (10 mg/ml) was added. The agarose was 
cast and allowed to cool to room temperature. The PCR product (25 µl) was mixed with 5 µl of blue 
loading dye (0.25% Xylene Cyanol, 30% glycerol) and loaded onto the gel. A 100 bp DNA ladder 
(GeneRuler, Fermentas) was loaded into a well adjacent to the samples to determine the size of the 
amplified DNA samples. The gel was run at 150 V for approximately 1-2 hours in 1x TBE buffer and 
visualized under ultra violet light using the Kodak Digital Science Electrophoresis Documentation 
and Analysis System 120 (VilberLourmat, France).  
 
3.1.2.5. Sanger Sequencing 
PCR products were purified and sequenced with the ABI PRISM DNA Sequencer model 377, Perkin 
Elmer at the Central Analytic Facility of Stellenbosch University. DNA sequences were then aligned 
and compared to the relevant genomic sequence of M. tuberculosis H37Rv reference strain 
(http://genolist.pasteur.fr/TubercuList) using DNAman version 4.1 (LynnonBiosoft, Quebec, Canada) 
to determine if polymorphisms are present in the genes domains of interest. 
 
3.1.3.  Statistical Analysis 
Statistical analysis was done in collaboration with Dr B Müller (Biomedical Sciences, Stellenbosch 
University). To test for an association between compensatory mutations and clustering, IS6110 RFLP 
patterns of the 365 isolates included were compared with RFLP patterns obtained from our full 
sample bank consisting of 2003 RFLP typed isolates with 564 different RFLP types identified. 
Statistical analyses were performed in IC Stata 10.0 (StataCorp LP, College Station, Texas, USA). 
Chi-squared analyses, univariate and multivariate logistic regression analyses were done to identify 
associations of compensatory mutations in rpoC with clustering, level of drug resistance, strain 
genotype, and different rifampicin resistance mutations in rpoB. A p-value <0.05 was considered 
statistically significant.  
 
3.2. Investigation of the expression of energy metabolism genes in response to rifampicin 
exposure 
 
3.2.1.  Strain selection 
MDR (n=4) and rifampicin mono-resistant clinical isolates (n=2) from genetically distinct 
evolutionary lineages (Beijing and Low Copy Clade (LCC)) were selected. The characteristics of 
these isolates were previously described (114). These isolates were characterised by an identical rpoB 






Table 3.3: Characteristics of the MDR and rifampicin mono-resistant isolates selected.  
Resistance 
profile 
Isolate Family Cluster 
rpoB 
mutation 




















R721 Beijing 209 
Ser531Leu None 
70 

























Legend to Table 3.3: 
* Isolates selected for protein analysis  
 
3.2.2.  Culture of M. tuberculosis isolates 
Preparation of freezer stock 
All Mycobacterium tuberculosis strains were initially grown on Löwenstein-Jensen (LJ) solid medium 
with continuous aeration for approximately three weeks at 37°C. After three weeks the buff coloured 
colonies that had a breadcrumb appearance were scraped from the LJ‟s. Primary cultures were set up 
by inoculation of the scraped colonies into 5 ml of 7H9 Middlebrook medium (Becton, Dickinson and 
Company, Sparks, USA) (supplemented with 10 % albumin-dextrose-catalase (ADC); 0.2 % (v/v) 
glycerol (Merck Laboratories, Saarchem, Gauteng, SA) and 0.1 % Tween80 (Becton, Dickinson and 
Company, Sparks, USA. These primary cultures were grown in filtered screw cap tissue culture flasks 
(Greiner Bio-one, Maybachstreet, Germany) without shaking at 37°C to mid-logarithmic phase 
(OD600= 0.6-0.8). Subsequently, the primary cultures were inspected for contamination by Ziehl-
Neelsen (ZN) gram staining and cultured on blood agar plates. M. tuberculosis, an acid fast bacterium, 
will retain dyes when heated and treated with acidified organic compounds, and will therefore appear 
pink in a contrasting background when the ZN test is done. M. tuberculosis does not grown on blood 
agar within two days. The primary cultures were then sub-cultured in 10 ml 7H9 Middlebrook medium 
supplemented with ADC and incubated at 37°C. After approximately 2 weeks of growth (OD 600 = 0.7-
0.8), the secondary sub-cultures were re-inspected for contamination and a 25 % glycerol stock (1:1 









3.2.3.  Protein Analysis 
As described previously (M. Bester, MSc thesis, 2009), a proteomic approach was followed to 
identify differential protein expression in clinical MDR M. tuberculosis isolates after rifampicin 
exposure. These clinical isolates (R451 and R439, see Table 3.3) displayed varying levels of 
rifampicin resistance. Briefly, two-dimensional electrophoresis and Matrix Assisted Lazer 
Desorption/Ionization Time of Flight (MALDI-TOF) analysis were used to identify differential 
protein expression after 24 hours of rifampicin (2 µg/ml) exposure. Proteins showing increased level 
of abundance after rifampicin exposure and which are involved in energy metabolism are shown in 
Table 3.4. 
 
Table 3.4: Proteins with increased expression involved in energy metabolism  
Accession 
nr 
Gene Protein Protein Function 
*
 
Rv3029c fixA Electron transfer 
flavoprotein beta- subunit 
Transfers electrons to main respiratory chain via ETF-
ubiquinone oxidoreductase (ETF dehydrogenase) 
Rv1308 atpA ATP synthase alpha chain Alpha chain (Regulatory unit) of FOF1 ATP synthase, 
which produces ATP from ADP in presence of proton 
gradient across membrane.  
R1446c opcA Putative oxpp cycle protein May be involved in functional assembly of glucose 6-
phosphate dehydrogenase 
Rv0462 lpdC Dihydrolipoamide 
dehydrogenase lpd 
Component of the alpha-ketoacid dehydrogenase 
complex 
Rv0363c fba Fructose bisphosphate 
aldolase 
Involved in glycolysis (catalytic activity) 
Rv0896 gltA2 Citrate synthase GltA2 Involved in tricarboxylic acid cycle (Krebs cycle, 
catalytic activity) 
RV1307 atpH ATP synthase delta chain 
ATPH 
FOF1 ATP synthase subunit delta. Either transmits 
conformational changes from CF(0) into CF(1) or is 
implicated in proton conduction 
Legend to Table 3.4: 
* Protein function according to http://genolist.pasteur.fr/TubercuList 
 
3.2.4. RNA extraction and gene expression analysis 
RNA extraction and gene expression analysis was done in collaboration with Dr GE Louw 
(Biomedical Sciences, Stellenbosch University). 
 
3.2.4.1. RNA extraction from M. tuberculosis cultures 
Each experimental culture was set up by inoculating 800 μl of the secondary sub-culture into 80ml 
enriched 7H9 medium (1:100 dilution) and incubating at 37°C until mid-log phase (OD600= 0.7-0.8). 
The 80 ml culture was then divided into 2 x 40 ml cultures. Rifampicin was added to one 40 ml 





TB drugs were added to the other 40 ml culture (control). Both cultures were then incubated at 37 °C 
for a further 24 hours. 
 
After antibiotic exposure, RNA was extracted as described previously (114). Briefly, five volumes of 
5M GITC (Sigma-Aldrich, St Louis, Germany) were added to one volume of each M. tuberculosis 
culture. The cultures were centrifuged (Eppendorf, Centrifuge 5810R) in 50 ml tubes (LASEC, South 
Africa) at 3 000 rpm for 20 minutes at 20°C. The supernatant was discarded and the bacterial pellet 
was transferred to a 2 ml Eppindorf tube (Merck, New Jersey, USA) and centrifuged at 13 000 rpm 
for 1 minute at room temperature. After centrifugation, the pellet was re-suspended in 1 ml TRIzol LS 
reagent (Invitrogen, CA, USA). The suspension was transferred to a 2 ml screw capped tube 
containing silica beads (IEPSA, Medical diagnostics, South Africa) and ribolysed using a FastPrep 
FP120 ribolyser (Bio101 SAVANT, Vista, USA) at 6 m/s for 4 x 20 seconds with 1 minute of cooling 
on ice between intervals. The tube was incubated for 5 minutes at room temperature before the lysed 
suspension was centrifuged at 12 000 rpm for 10 minutes. The supernatant and cellular debris was 
transferred to a 2 ml Phase Lock gel tube (Merck New Jersey, USA) containing 300 µl chloroform 
(Sigma-Aldrich, St Louis, Germany). The tube was inverted rapidly for 15 seconds, followed with 
periodically inversion for an additional 2 minutes. The tube was incubated for 5 minutes at room 
temperature and then centrifuged at 12 000 rpm for 10 minutes. The top aqueous layer was then 
transferred to a clean 1.5 ml tube containing an equal volume of isopropanol and incubated overnight 
at 4ºC. Precipitated nucleic acids were collected by centrifugation at 12 000 g for 30 minutes at 4ºC. 
After centrifugation, the RNA pellet was washed with 1 ml 70 % ethanol, inverted several times and 
centrifuged at 12 000 rpm for 10 minutes at 4°C. After centrifugation, the ethanol was aspirated and 
the RNA pellet was allowed to air-dry at room temperature. The RNA pellet was dissolved in 70 µl 
RNase-free water (Ambion, Applied Biosystems, CA, USA) and stored at -80°C for subsequent 
experiments.  
 
3.2.4.2. DNAse treatment of extracted RNA 
Contaminating chromosomal DNA was digested with RQ1 RNase-free DNase (Promega, WI, USA) 
according the instructions of the manufacturers. 15 µl of RNA was added to 4 µl DNase and 4 µl 
DNase Buffer, followed by incubation for 30 minutes at 37°C. After incubation the DNase treated 
RNA was stored at -80°C for further use.  
 
3.2.4.3. Phenol purification 
The DNase treated sample was made up to a final volume of 200 µl with RNAse free water. An equal 
volume of phenol:chloroform (4:1) (Sigma-Aldrich, St Louis, Germany) was added to the diluted 
RNA and mixed by gentle inversion. The RNA/phenol:chloroform mix was incubated for 10 minutes 





temperature. The top layer was transferred to a clean tube and 1/10 volume of sodium acetate (pH 5.2) 
(Merck, New Jersey, USA) and 2.5 volumes of 100 % ethanol (Merck, New Jersey, USA) were added 
to the RNA. The RNA was incubated for 1 hour (or overnight) at 4°C. The precipitated nucleic acids 
were collected by centrifugation at 12000 rpm for 30 minutes at 4°C. After centrifugation, the pellet 
was washed with 1 ml 70% ethanol, inverted several times and centrifuged at 12 000 rpm for 10 
minutes at 4°C. Thereafter, the ethanol was aspirated and the purified RNA pellet was allowed to air-
dry at room temperature. The RNA pellet was dissolved in 70 µl of RNase-free water and stored at -
80°C till further use. The RNA quality and quantity were assessed by using the Experion analyzer 
with the Experion Software version 2.01 (Bio-Rad Laboratories, Hercules, CA 94547) and PCR 
amplification using the extracted purified RNA as the template in combination with the primers listed 
in Table 3.5. 
 
Table 3.5: Primers used to assess the quality of the extracted RNA 
 Gene 
name 






Forward 5′ TAGGATCCATGCGATCAGAACGTCTCCG  3′ 
695 
62 
Reverse 5′ GATAAGCTTCTAGGATCTATGGCTGCCGAGT  3′ 62 
Legend to Table 3.5: 
* DNA melting temperature 
 
3.2.4.4. cDNA synthesis of purified RNA 
cDNA was synthesized from 1 µg highly purified RNA using the QuantiTect Reverse Transcriptase 
kit according to the manufacturer‟s instructions (Southern Cross Biotechnologies). Briefly, 1 µg RNA 
was mixed with 2 µl genomic DNA Whipeout Buffer and RNase-free water (to a volume of 14 µl) 
and incubated for 2 minutes at 42°C. After incubation Quantiscript Reverse Transcriptase, 
Quantiscript RT buffer, and RT Primer Mix was added to the RNA mix and incubated for 15 minutes 
at 42°C. After incubation the mix was incubated for 3 minutes at 95ºC to inactivate the Quantiscript 
Reverse Transcriptase. 
 
3.2.4.5. Primer design of Quantitative Real Time PCR (QRT-PCR) of candidate genes 
PCR primers (Table 3.6) for quantitative reverse transcriptase analysis of the candidate genes in Table 
3.4 in addition to genes (Rv1312, Rv1303) flanking the ATP synthase operon, its regulator Rv1846c 
and the housekeeping gene 16s rRNA were designed against the whole genome sequence of the M. 
tuberculosis H37Rv reference strain (http://genolist.pasteur.fr/TubercuList) using Primer software 3 







3.2.4.6. Quantitative Real Time PCR 
A standard Master mix was set up by adding 2µl of Light Cycler Fast start DNA Master PLUS SYBR 
Green I reaction mix (Roche Applied Science, Germany), 2 µl forward and reverse primer (10µM) of 
each candidate gene (Table 3.6), 11µl of RNase-free water. Subsequently, 9 μl aliquotes of the master 
mix was added to 1 μl cDNA. A no template control was added to assess contamination. RT-qPCR 
was done by using the Lightcycler 2.0 instrument (Roche Applied Science). A four step PCR 
parameter protocol was used: (i) Activation program (95°C for 15 minutes); (ii) RT PCR program 
repeated for 40 cycles (95°C for 15s for denaturation, 56/58
o
C for 30s for annealing and 72°C for 30s 
for polymerase elongation); (iii) Melting curve program (95°C for 0s, 60°C for 15s, 90°C for 0s with 
a heating rate of 0.1°C/s) and (iv) Cooling down program of 40°C for 10s. Each RT-qPCR experiment 
was done on duplicate biological samples that were each assayed in triplicate.  
 
Table 3.6: Primers used for the gene expression assessment of the energy metabolism genes 










Forward  5‟ ACGACCATCGTGGTCCTGAT 3‟ 
801 146 58 
Reverse 5‟ATCTGTAGCGCTTCCTCCAC 3‟ 
atpA 
Forward  5‟ GAGGAGCAAGTGGTTTCGAT 3‟ 
1650 141 58 
Reverse 5‟GTCCCGGATCTCAGTCAAAA 3‟ 
opcA 
Forward 5‟ CGGTCAACAAGAAGCTCGAC 3‟ 
912 115 56 
Reverse 5‟ TCGATGGACTCTTCCAGCAT 3‟ 
lpdC 
Forward 5‟ GCGAGGTGACCTTCGACTAC 3‟ 
1395 112 58 
Reverse  5‟ TGGATCTCGGTGATCTTGTTC 3‟ 
Fba 
Forward 5‟ GGGGTCAAAGACATGGTGAC 3‟ 
1035 192 60 
Reverse 5‟ CGACTGGAACAAAGGATTGC 3‟ 
gltA2 
Forward 5‟ GGTCAAATTGATGGGTTTCG 3‟ 
1296 176 58 
Reverse 5‟ TGCGTTCGATGAAGTAGTCG 3‟ 
atpH 
Forward  5‟ GAGGCGAGTCAAGCTCACAC 3‟  
1341 113 60 
Reverse 5‟ TGGGCCTCTAGTTGTTCTGC 3‟ 
Rv1312 
Forward 5‟ GCGTTCTACCGGCTTTCTAGT 3‟ 
444 141 56 
Reverse 5‟ GCACAGTTCCACAACGACAA 3‟ 
Rv1303 
Forward 5‟ CTGACGGTCGGGATGTTCTT 3‟ 
486 108 56 
Reverse 5‟ TTTTAACGGGTGCTCTTTGG 3‟ 
Rv1846c 
Forward 5‟ GGTCATGGACCATTTGTGG 3‟ 
417 140 58 
Reverse 5‟ GCAGCACGAGGTTCTTCTTT 3‟ 
Legend to Table 3.6:  





3.2.4.7. Statistical analysis 
Both 16S rRNA and sigA were included as reference genes, but 16S rRNA was used for normalization 
of mRNA levels, because in the experiments 16S rRNA expression levels were the most stable. The 
level of gene expression of each individual gene was quantified by the delta-delta Ct calculation in 
which the relative abundance of the target gene was normalized relative to the levels of the reference 
RNA transcripts (16S rRNA). Data analyses were done according to the delta-delta CT equation R=2 -
(LCT sample -LCT control). Only experiments with a standard deviation of <0.5 were included for 
analysis. Significant fold changes were identified based on The Relative Expression Software Tool -
384 (REST-384©) that assigns significance with a significance level of 5% (147).  
 
3.3. Selection and characterization of rifampicin resistant in vitro mutants 
3.3.1. Strain selection 
To investigate the genotype and phenotype of in vitro generated rifampicin resistant mutants in a 
clinical strain background, a pan susceptible clinical isolate from the Beijing family (cluster 208 
(K636)) and the laboratory strain H37Rv (ATCC 27294) were selected as progenitor strains for the 
Luria Delbrück Fluctuation assay. Freezer stocks of these isolates were prepared as described in 
section 3.2.2. 
 
3.3.2. Selection of rifampicin resistant mutants by the Luria Delbrück Fluctuation assay 
3.3.2.1. Growth curves 
A 1:100 dilution of the freezer stock was inoculated in 7H9 Middlebrook media supplemented with 
ADC. The culture was incubated at 37°C for 28 days and the growth of the culture was assessed with 
daily OD600 readings. Additionally, 1 ml of the culture was serially diluted by factors of 10 at different 
time points (day 1, 2, 3, 7, 14, 21, 28 after initial inoculation) and plated on 7H10 Middlebrook 
(Becton, Dickinson and Company, Sparks, USA) solid media supplemented with OADC (Becton, 
Dickinson and Company, Sparks, USA). Plates were incubated at 37 °C for 21 days after which the 
Colony forming Units (CFUs) on each plate were determined.   
 
3.3.2.2. Selection of in vitro rifampicin resistant mutants by the Luria Delbrück Fluctuation 
assay 
In vitro mutants were selected according to a modified Luria Delbrück fluctuation essay (132). 
Briefly, a 1:100 dilution of the freezer stock was cultured in 7H9 Middlebrook media supplemented 
with ADC and incubated at 37°C to an OD of 0.8 (corresponding to approximately 10
8 
CFU/ml). The 
culture was diluted in 500 ml of 7H9 Middlebrook media supplemented with ADC (to yield 
approximately 10
3
 CFU/ml) and 5 ml aliquots were dispensed in 100 tissue culture flasks and 
incubated for 32 days at 37°C. The entire culture volume were transferred to 50 ml centrifuge tubes 





suspended in 1 ml of 0.05% Tween. The tube was centrifuged for 5 minutes at 3000 rpm and the 
supernatant were aspirated, leaving a small amount of liquid. The bacterial pellet was re-suspended 
and glycerol stocks (25%, 1:1 v/v, 500µl culture and 500µl 50% glycerol) was prepared from half of 
the volume of the progenitor culture before rifampicin selection. The other half volume was plated on 
7H10 solid Middlebrook media supplemented with OADC and contained 2µg/ml rifampicin. The 
plates were incubated at 37°C for 28 days. Single colonies were picked from these plates and sub-
cultured in 5 ml 7H9 Middlebrook media supplemented with ADC until a growth OD600 of 0.8 was 
reached. Cultures were inspected for contamination and a 25% glycerol stock (1:1 v/v, 500µl culture 
and 500 µl 50% glycerol) was prepared and stored at -80°C. 
 
3.3.3. Targeted gene sequencing 
To determine the frequency of mutations in rpoB, the Rifampicin Resistance Determining Region 
(RRDR) was PCR amplified using DNA templates prepared from the glycerol stocks as described in 
section 3.1.2.1. The resulting amplicons were purified and sequenced using the Sanger method at 
Central Analytic Facility, Stellenbosch University. 
 
3.3.3.1. Primer design 
Primers (Table 3.7) for the amplification of the RRDR in the rpoB genes were designed using Primer 
software 3 version 0.2 (Whitehead Scientific, South Africa), and the whole genome sequence of the 
M. tuberculosis H37Rv reference strain (http://genolist.pasteur.fr/TubercuList).  
 
Table 3.7: Primers used for the amplification of the RRDR 
  Primer Sequence Product size (bp) Tm (°C)* 
rpoB 
Forward 5‟ TGGTCCGCTTGCACGAGGGTCAGA 3‟ 
437 
78 
Reverse 5‟ CTCAGGGGTTTCGATCGGGCACAT 3‟ 76 
Legend to Table 3.7:  
* DNA melting temperature 
 
3.3.3.2. PCR (Touch down) 
The PCR reactions were executed in 25 µl reaction volumes. The PCR master-mix consisted of 1X 
reaction buffer, 2mM MgCl2, 200 µM of each deoxyribonucleotide triphospate (dNTP), 50 µM 
Forward primer, 50 µM Reverse primer, 1.25 U Hotstar Taq polymerase, 1.25 µl of the crude DNA 
template, and H2O to make up a final volume of 25 µl. The reaction mixtures were heated in the 
thermal cycler (GeneAmp PCR System 2400, Applied Biosystems, Foster City, CA, USA) at the 
following conditions: an initial denaturing step at 95ºC for 15 minutes, followed by 2 cycles of a 
denaturing step of 94ºC for 1 minute and an annealing step at Tm (72ºC) for 1 minute. This is followed 





minute. This is followed by another 2 cycles of a denaturing step at 94ºC for 1 minute, an annealing 
step at Tm (70ºC) for 1 minute. This is followed by 40 cycles of a denaturing step at 94ºC for 1 
minute, an annealing step at Tm (62ºC) for 1 minute, an extension step at 72ºC for 1 minutes, and a 
final extension step at 72ºC for 10 minutes.  
 
Subsequent gel electrophoresis and Sanger sequencing were done as described in section 3.1.2.4 and 
3.1.2.5. 
 
3.3.4. Rifampicin MIC determination 
The Rifampicin MIC for the different in vitro mutants (generated by the Luria Delbruck Fluctuation 
assay) was determined in the BACTEC MGIT 960 instrument (BD Bioscience, MD, USA) according 
to the manufacturer instructions. Briefly, to initiate a starter culture, 800 µl of OADC were inoculated 
with 200 µl of the M. tuberculosis isolate freezer stock in the MGIT 960 media. The culture was 
incubated in the MGIT instrument at 37°C until a positive growth reading was reached. Two days 
after positive growth was reached, a drug free growth control tube was prepared. This was done by 
diluting the positive culture suspension (1:100) using sterile saline and inoculating 500 µl of this 
dilution into a MGIT tube supplemented with 800 µl OADC. Subsequently, 500 µl of the undiluted 
positive culture suspension was inoculated in MGIT tubes supplemented with 800µl OADC and 100 
µl of the specific rifampicin concentration (with final concentration ranging between 10 and 200 
µg/ml). The MGIT culture tubes were placed in the BACTEC MGIT 960 instrument and growth was 
continuously monitored using EpiCenter (version 5.75A) TBeXist software (BD Bioscience, 
Erembodegem, Belgium) for approximately 14 days.  
 
The EpiCenter, version 5.75A, equipped with the TB exist module, were used for the analysis of the 
data generated by the MGIT 960 instrument. Results were interpreted as follows. At the time when 
the growth control tube reached a growth unit (GU) > 400, a strain would be considered as resistant if 
the GU of drug containing tube was ≥ 100. If the GU of the drug containing tube was < 100, the tube 
was incubated for a further 7 days. If the GU was still <100 after 7 days, the strain would be 
considered as sensitive. If the GU reached > 100 within the 7 days (after the growth control reached a 
GU of >400), the strain would be considered as intermediate resistant to the respective drug 
concentration (186).    
 
The MIC is defined the minimum concentration of an antibiotic that is required to kill 99% of the 
bacterial cells in that culture (27). However, for this study we defined the MIC as the level of 







3.3.5. Statistical analysis 
A two sample proportional test (confidence level of 95%) using the R statistical package 
(http://www.r-project.org) were used to test whether there was a statistical difference in the 
frequencies of the different rpoB mutations between the different genetic backgrounds and findings 
from previous studies (82).   
 
3.4. Identification of genetic variants responsible for varying rifampicin resistance levels 
3.4.1.  Strain selection 
To identify genetic variants resulting in increased rifampicin resistance, two in vitro rifampicin 
resistant mutants and five clinical MDR isolates with varying rifampicin resistance were selected for 
whole genome sequencing on the Illumina platform (Table 3.8). 
 













































K636 Beijing 2 208 Wild type None < 2 
R179 Beijing 
2 220 S531L 
inhA -15 prom 
embB306 Met306Val 
pncA 103 Tyr103Ter 
140 
R257 Beijing 30 
R451 Low Copy Clade 





R439 Low Copy Clade 60 
 
3.4.2. DNA extraction 
DNA was extracted as previously described (223). In summary, 100 ul of freezer stock from each 
isolate were inoculated onto two petri dishes containing 7H10 media supplemented with OADC and 
incubated at 37°C for two weeks or until sufficient growth was observed. Thereafter, the outer surface 
of the petri dishes were decontaminated with Incidin Plus (Ecolab, Minnesota, USA) and placed in a 
biosafety autoclave bag and transferred to a prewarmed fan oven at 80°C for 1h to ensure heat killing. 
Colonies were gently scraped with a disposable 10 µl loop from the 7H10 media surface and 
transferred to a 50 ml tube containing approximately 20 glass beads (4mm in diameter) and 6 
millilitres of extraction buffer (5% sodium glutamate, 50 mM Tris-HCl (pH 7.4) and 25mM EDTA)). 
The 50 ml tubes containing the extraction buffer cell suspension were vortexed to disrupt the colonies. 
Lysozyme (25 mg, Roche, Germany) and RNAse A (50 µg, Roche, Germany) were then added and 





600 µl of 10x proteinase K buffer (5% sodium dodecyl sulphate, 100nM Tris-HCl (pH 7.8), 50mM 
EDTA) were added and the suspension was incubated for a further 16 hours at 45°C to digest all 
bacterial proteins. An equal volume of phenol/chloroform/isoamyl alcohol (24:23:1) was added and 
the mixed intermittently over a period of 2 hours at room temperature. After centrifugation at 3000 x 
g for 20 minutes, the aqueous phase was aspirated and an equal volume of chloroform/isoamyl 
alcohol (24:1) was added. After centrifugation at 3000 rpm for 20 minutes, the resultant DNA was 
precipitated with the addition of 600 µl 3 M sodium acetate (pH 5.2) and an equal volume of 
isopropanol and immediately collected on a glass rod. The DNA was washed with 70% ethanol, the 
air-dried pellet, re-dissolved in 300 µl TE (10 mM Tris-HCl (pH 8.0), 1mM EDTA) and stored at -
20°C. The concentration of the extracted DNA was measured using the NanoDrop spectrophotometers 
(Thermo Fisher Scientific, Waltham, Massachusetts, USA). 
 
3.4.3. Illumina sequencing 
Sequencing of the  M. tuberculosis clinical isolates (n=5) and in vitro selected mutants (n=2) were 
done by Partners Healthcare Center for Personalized Genetic Medicine, Harvard Medical School, 
Boston, USA using the Illumina sequencing platform version 1.5 to generate pair-end reads with a 
size of 100 base pairs. DNA libraries were prepared by Dr. Gail Louw (Department of Biomedical 
Sciences). 
  
3.4.4. Computational analysis of whole genome sequences 
Computational analysis was done in collaboration with Prof G Sherlock (Stanford University, USA), 
Dr D Kvitek (Stanford University, USA) and Mmakamohelo Direko (SANBI, UWC). The workflow 
for the analysis of the whole genome sequences produced on the Illumina platform is summarized in 
Figure 3.1. 
 
3.4.4.1. Data sources 
The fastq files of the genomes sequenced were acquired from the Gateway for Integration of 
Genomic-Proteomic Applications and Data (GIGPAD) platform (http://pcpgm.partners.org/it-
solutions/gigpad). The reference genome (M. tuberculosis H37Rv) in fasta format, genome summary 
information and genome sequences per gene was downloaded from 
http://genome.tbdb.org/annotation/genome/tbdb/MultiDownloads.html.  
 
3.4.4.2. Fastq file format 
The fastq format (Figure 3.2) is a text-based format for the storing of biological sequences and the 







Figure 3.1: Summarized workflow for the computational analysis of whole genome sequences 
Legend to Figure 3.1: 
Computational tools are highlighted in blue 
 
 
Figure 3.2: Representative of a typical read from a fastq file produced by the Illumina sequencing 
platform version 1.5. 
 
Legend for Figure 3.2: 
1. Begins with a „@‟ character, which is followed by the sequence identifier 
2. The raw sequence letters 
3. Begins with a „+‟ character and is optionally followed by the same sequence identifier 






3.4.4.3. Quality assessment and quality control of the fastq reads 
The raw sequence reads were assessed with the FastQC software to validate the quality of the reads 
and to determine whether the data included any factors that would influence the subsequent analysis. 
This java-based program takes fastq files as input and the results obtained are produced in a HTML 
format. FastQC analysed the raw data through a 7 steps module which include the following:  
1. The general statistics included a description of the platform used, input file type,  the amount of 
reads processed, read length and percentage GC content. 
2. Calculated the per read quality score using the means scores of all the reads. 
3. Calculated the per base sequence content to determine the distribution of the four nucleotides 
throughout the reads. 
4. Calculated the GC content throughout the reads and compared it to a theoretical normal 
distribution and mean value. 
5. Calculated the possibility of contamination in the reads. 
6. Calculated the number of uncalled bases throughout the reads. 
7. Calculated the amount of duplicate sequences. 
 
3.4.4.4. Read alignment and mapping 
The raw sequence reads were aligned to the reference genome of M. tuberculosis H37Rv with two 
respective aligners, Burrows-Wheeler aligner (BWA) (107) and Novoalign 
(http://www.novocraft.com/main/index.php). Using two different aligners will minimize the 
identification of false positive variants since the aligners use different algorithms. Both aligners 
produce a Sequence Alignment/Map (SAM) format. This format is compact in size and allows for 
most operations on the alignment to work on a stream without loading the entire alignment into the 
memory. This format can also be indexed, allowing the efficient and fast retrieval of all reads at a 
specific chromosomal locus. 
 
Burrows-Wheeler aligner (BWA) 
BWA aligns relative short reads to a reference genome by implementing two algorithms: BWA-short 
(for reads shorter than 200bp) and BWA-SW (for longer reads around 100kbp). BWA-short was used 
for this study‟s analysis since it does gapped global alignment, supports paired-end reads and 
produces results with a low error rate (< 3%). It also requires an indexed reference genome for the 
alignment step. This was done by using the “faidx” command from SAMtools. BWA takes fastq reads 
as input and uses the “aln” command to find suffix array (SA) coordinates of good hits for every read. 
Subsequently the “sampe” command was used to convert the SA coordinates into chromosomal 








Novoalign also aims to produce fast and accurate alignments. This software also requires the 
reference genome to be indexed. This was done by the “Novoindex” command, using default values 
of a k-mer indexing size of 13 and a indexing step size of 1. Novoalign takes fastq reads as input and 
uses the Needleman Wunsh algorithm to compute the alignment. The software also does global 
gapped alignment and for this analysis the default value of 6 was used, thus allowing six mismatches 
per alignment. 
 
3.4.4.5. SAM file validation 
The “ValidateSamFile” command from Picard (http://picard.sourceforge.net) was used to report on 
the validity of the SAM file. 
 
3.4.4.6. Converting SAM file to BAM file  
SAM Tools (http://samtools.sourceforge.net) provide a set of various utilities for manipulating and 
post-processing of SAM files. This includes tools to sort, merge, and index SAM files. The SAMtools 
command “view” were used to convert the SAM alignment files to the binary (BAM) format 
 
3.4.4.7. Alignment statistics   
SAMtools was used to compute statistics about the alignment process. The “flagstat” command 
calculates the total number of reads used as input in the mapping software. Additionally it also 
calculates: the number of duplicate reads; the number of reads that mapped to the reference genome 
and the number of reads which properly paired when aligned to the reference genome. 
 
3.4.4.8. Post alignment processing of BAM files 
BAM files were subsequently processed to correct for errors incorporated during the alignment step. 
 
Coordinate sorting and indexing of BAM files 
The SAMTools functions “sort” and “index” were used to convert the BAM file in a format that is 
easy to manage and read. The BAM file is sorted by coordinate to avoid loading extra alignments into 
computational memory. 
 
Local realignment around Indels (short insertions and deletions)  
Insertions and deletions might influence the alignment of reads to its reference genome, which may 
result in many bases mismatching the reference near the misalignment (which could be misinterpreted 
for single nucleotide polymorphisms (SNPs). To minimize the number of mismatching bases across 
all reads, the Genome Analysis Toolkit (GATK) (Broad Institute, Cambridge, UK) were used to 





intervals which were misaligned, by using the Realigner Target Creator tool. Subsequently, the 
IndelRealigner tool was used to realign the suspicious intervals to the reference genome, and thereby 
fixing the misaligned reads. 
 
Co-ordinate sorting and indexing of Realigned BAM files 
The realigned BAM files were sorted with Picard‟s (http://picard.sourceforge.net/) “sortsam” function 
and indexed with Samtools‟ “index” function. 
 
Removal of PCR duplicates 
Duplicate reads may be produced with PCR amplification during library construction. To mitigate the 
biased introduced by PCR amplification, the Picard command “Mark Duplicates” were used to locate 
duplicate molecules in the BAM file, which were flagged in the output BAM file. 
 
3.4.4.9. Variant calling 
The H37Rv reference genome was used to identify SNPs and short insertions and deletions (Indels) in 
the respective genomes. For this purpose two different variant callers were used to minimize the 




The UnifiedGenotyper tool from GATK was used for SNP and Indel calling and produces an output 
in the Variant call format (vcf) format. Stand_call_conf were set to 50. This will allow a minimum 
phred-scaled confidence threshold of 50, variants with a confidence value ≥ 50 are emitted as called 
sites. Stand_emit_conf were set to 10. Variants with a phred-scale confidence value ≥ 10 but less than 
the calling threshold of 50 are emitted but marked as filtered. The output vcf file contains information 
about the position, the alternative sequence and thePHred scaled probability that the alternative 
polymorphism exist at this position. The Phred scale (Q) is defined as a property which is 
logarithmically related to the probability that there might be an error in the actual base-calling. Q = -
10log10, a value of 10 indicates that there is a 1 in 10 chance of error. The vcf file also contains 
information specific to the alternative base, including the number of reads bridging that position, as 
well as the number of reads that contained the reference and alternative base at that position. 
 
Sam Tools 
SAMtools‟ function “mpileup” were used create a pileup of the reads relative to the reference genome 
and subsequently identifies SNPs relative to the reference sequence. Default parameters were used. 
Indels called by SAM tools were found to be inconsistent and after considered evaluation, it was 





contains information about the position, the alternative sequence and quality score in PHRED scale of 
each variant. The file also contains specific information about the variant, including the number of 
reads bridging that position. 
 
3.4.5.  Extraction of overlapping SNPs generated by the various pipelines 
As discussed in previous sections two different aligners (BWA and Novoalign) and two different 
variant callers (GATK and SAM Tools) where used to minimize the identification of false positives 
variants (Figure 3.1). Therefore, four strategies (pipelines) where used to identify SNPs, these where 
namely BWA-GATK, BWA-SAMTools, Novoalign-GATK and Novoalign-SAMTools. For indel 
calling, only two pipelines where used: BWA-GATK and Novoalign-GATK. Thus variants were only 
considered in further analysis if identified with all pipelines. In-house python scripts written by Mrs 
Michelle Daya (Department of Biomedical Sciences, Stellenbosch University) were used to extract 
overlapping SNPs generated by all four pipelines (Figure 3.3). For this purpose SNPs present in both 
vcf files created by BWA-GATK and BWA-SAM Tools were first extracted. Likewise, SNPs present 
in the both vcf files created by Novoalign-GATK and Novoalign-SAMTools were also extracted. 
SNPs present in both of these newly created vcf files were extracted to create a final vcf file that 
contain high confidence SNPs identified by all four pipelines. A similar approach was followed to 
extract Indels present in both vcf files created by BWA-GATK and Novoalign-GATK. The statistical 
package R (http://www.r-project.org) was used to create Venn diagrams to illustrate the distribution of 







Figure 3.3: Strategy followed to identify high confidence SNPs from the four described pipelines 
Legend to Figure 3.3 
High confidence SNPs identified by the four described pipelines are shown in green.  
 
3.4.6.  Reconstruction of a phylogenetic tree 
A python script written by Mrs Michelle Daya (Biomedical Sciences, Stellenbosch University) were 
used create a concatenated sequence of all polymorphic sites identified for each genome. The 
concatenated sequences were then aligned using Bio-Edit (v 7.1.3) (71) and used to construct a 
maximum likelihood phylogenetic tree (standard parameters) using MEGA 5..05 (207). 
 
3.4.7. Annotation and functional classification of SNPs/Indels 
Perl scripts were written to: 1) annotate the identified SNPs, 2) calculate the predicted aminoacid 
change for SNPs located in genes, 3) annotate the identified Indels 4) calculate the effect of indels on 






3.4.8. Comparison of variants between genomes 
In-house python scripts written by Mrs Michelle Daya were used to compare the high confidence 
variants from the sequenced genomes. 
 
3.4.9. Validation of high confidence variants 
High confidence variants identified in the comparison of sequenced genomes were first validated by 
visualization using GenomeView (2). Subsequently primers (Table 3.9) were designed to amplify and 
sequence the surrounding regions of the variants as described in sections 3.1.2.2 – 3.1.2.5. 
 







Forward 5‟gtggatcctggaaaatgtcg 3‟ 
509 
60.32 
Reverse 5‟ gtacacgggtttagcgttcc 3‟ 59.50 
malQ 
Forward 5‟ atcccgatgcctcaggtgt 3‟ 
395 
62.87 
Reverse 5‟ gatgatgtggtcgatgcgta 3‟ 60.51 
TB16.3 
Forward 5‟ gatccaggcgaggtgatg 3‟ 
544 
60.16 
Reverse 5‟ cggtggataccaccaacact 3‟ 60.59 
fadD12 
Forward 5‟ gaaaccctcaagcagcatgtc 3‟ 
309 
62.10 
Reverse 5‟ ggcgcctaggtacactcctg 3‟ 62.11 
lpqN 
Forward 5‟ ttcaacatcaagaccgacagc 3‟ 
644 
61.23 
Reverse 5‟ ttagggcgtgatggtcgtc 3‟ 62.03 
lpqQ 
Forward 5‟ cggaaccgactggtcagagt 3‟ 
329 
62.64 
Reverse 5‟gccggttcaatacccaacac  3‟ 62.45 
mprA 
Forward 5‟tcgctttccttcaatggcta 3‟ 
362 
60.85 
Reverse 5‟ caggtcggagaacctcatgg 3‟ 62.98 
ndhA 
Forward 5‟ cacagcgaccagactgaagg 3‟ 
363 
62.03 
Reverse 5‟ accgtggtcatgtccatcaa 3‟ 62.25 
rpoB 
Forward 5‟ agggtcagaccacgatgacc 3‟ 
695 
62.36 
Reverse 5‟ gacgagggcacgtactcca 3‟ 62.27 
Rv0283 
Forward 5‟ cggtgagttcagcgacga 3‟ 
400 
62.25 
Reverse 5‟ gggccgaatcaacgagaata 3‟ 62.21 
Rv1225c 
Forward 5‟ gtgcttcctggtgaacaacg 3‟ 
390 
61.69 
Reverse 5‟ ccgatcatgaccatctgctg 3‟ 62.64 
Rv1226c 
Forward 5‟ ttggtttttcaccacctaccg 3‟ 
332 
62.01 
Reverse 5‟ataccgcaaccacgacgact  3‟ 62.82 
Rv3108 
Forward 5‟ tgtcagcgtttgaggacgat 3‟ 
647 
61.81 
Reverse 5‟gcgcctcaagagagtttcgt  3‟ 61.99 



























4.1. Epidemiological relevance of compensatory mutations in rpoA/C 
A well-characterized convenience sample of 67 drug-susceptible and 298 drug-resistant, clinical M. 
tuberculosis isolates was tested for the presence of putative compensatory mutations in rpoA and 
rpoC. Initial screening of 243 rifampicin-resistant isolates from this collection identified eight isolates 
(3.2%) harbouring distinct mutations in rpoA (Figure 4.1A). These mutations were D57N, T63T, 
S165I, D190G, and E319K. Given the infrequent occurrence of rpoA mutations in this sample set, the 
remainder of the collection was not further assessed and mutations identified in rpoA were excluded 
from further analyses.  
 
In contrast, non-synonymous mutations in rpoC were detected in 23.8% of the rifampicin-resistant 
clinical isolates (60/252 isolates), which all also harboured mutations in RRDR of rpoB (Figure 4.1B). 
However, mutations in rpoC were absent from all 113 rifampicin-sensitive isolates tested. Altogether, 
eight different non-synonymous mutations in rpoC (G332R, F452C, D485Y, V483G, V483A, I491T, 
Q523E, and H525Q) accounted for all non-synonymous mutations detected. In addition, one 
synonymous substitution (A542A) was identified. This mutation was previously reported to be a 
phylogenetic marker for the LAM family of M. tuberculosis strains and therefore excluded from 
further analyses (40). 
 
 
Figure 4.1 Synonymous and non-synonymous mutations identified in rpoA (a) and rpoC (b) of 
isolates collected from the Western Cape, South Africa. Each star indicates the presence of a mutation 






The non-synonymous mutations detected in the rpoC gene showed clear evidence of convergent 
evolution, suggesting they were positively selected among rifampicin-resistant strains. Specifically, 
genotyping of our collection of clinical M. tuberculosis isolates highlighted the independent 
emergence of putative compensatory mutations in rpoC. Three (G332R, V483G, I491T) of the eight 
non-synonymous mutations detected, independently evolved in phylogenetically distantly related 
strain families as defined by spoligotyping (Figure 4.1).  Five of the eight compensatory mutations in 
rpoC (G332R, V483G, V483A, I491T, Q523E) were reported previously in MDR M. tuberculosis 
strains from various countries including Russia, Ghana, Abkhazia/Georgia, Kazakhstan and 
Uzbeksitan (34, 40). Mutations at amino-acid positions 452, 485 and 525 of rpoC were also detected 
previously, albeit with different amino-acid changes (previously, F452S, D485N, D485H, H525N 
while here, F452C, D485Y and H525Q) (34, 40).   
 
To test whether mutations in rpoC were associated with increased transmissibility of drug-resistant M. 
tuberculosis, we compared the presence of rpoC mutations between isolates belonging to a recognized 
IS6110 RFLP cluster versus isolates showing unique RFLP patterns. Among rifampicin-resistant 
isolates with clustered RFLP patterns, 30.7% (50/163 isolates; 95% CI: 23.7%-38.4%) harboured 
mutations in rpoC; significantly more than among rifampicin-resistant isolates with non-clustered 
RFLP patterns (5/40 isolates; 12.5%; 95% CI: 4.2%-26.8%; Fisher‟s exact test p<0.05) (Figure 4.2).  
Mutations in rpoC were detected in one third of the RFLP clusters present among rifampicin-resistant 
isolates (in 12/35 RFLP clusters) (Figure 4.2). Two of these RFLP clusters showed two distinct rpoC 
mutations and a third cluster harboured four different rpoC mutations. Thus, mutations in rpoC were 
acquired at least 17 times among the 35 RFLP clusters while only 5 of 40 non-clustered RFLP types 







Figure 4.2 Proportion of rifampicin-resistant isolates or IS6110 RFLP types/clusters harbouring 
rpoC mutations 
* Number of isolates classified as either clustered or non-clustered based on IS6110 RFLP type harbouring an 
rpoC mutation 
** Number of IS6110 RFLP types classified as either unique or clustered harbouring an rpoC mutation 
 
Comparing the proportion of rpoC mutations across isolates with various degrees of drug resistance 
showed that this proportion increased significantly towards higher levels of drug resistance with 
42.6% of XDR-TB isolates harbouring non-synonymous rpoC mutations (p=0.001; Table 4.1). 
Similarly, rpoC mutations were non-randomly distributed among different families of strains. In 
particular, a genotype of “atypical” Beijing strains known as the R86 cluster showed a four times 
higher proportion of isolates harbouring rpoC mutations than isolates belonging to other genotypes 
(14.4% versus 56.9% among rifampicin resistant isolates; p<0.001; Table 4.1). 
 
Interestingly, the presence of non-synonymous mutations in rpoC was significantly associated with 
the rpoB S531L mutation (p<0.001; Table 4.1). Among isolates harbouring this mutation, 38.3% also 
harboured rpoC mutations while only 4.9% of the isolates with other rpoB mutations exhibited 
mutations in rpoC. A broad range of rpoC mutations was detected among isolates with an rpoB 
S531L mutation with the rpoC V483G mutation being most frequently detected. Only two isolates 
with rpoC mutations did not show an rpoB S531L mutation. Instead, these isolates harboured the 
L511P and D516V mutations in rpoB and both showed a V483G mutation in rpoC. A multivariate 
logistic regression model adjusted for different types of rpoB mutations, strain genotype and degree of 





and the R86 genotype on the one hand, and the rpoB S531L mutation on the other hand (Table 4.1). 
By contrast, the association between XDR-TB and rpoC mutations was not supported in this 
multivariate model, probably because it was confounded by an underlying association between the 
R86 genotype and XDR-TB. 
 
Table 4.1 Logistic regression analysis for factors influencing the presence of compensatory 
mutations in rpoC 
Characteristics Variants 
  Unadjusted   Adjusteda 
  Freq   OR   
p-
value 
  Freq   OR   
p-
value 
Drug resistance groupb 
R mono   55   N/A   N/A   12   N/A   N/A 
MDR s.s.   101   5.7   0.022   64   0.4   0.365 
Pre-XDR   49   18.3   <0.001   28   1.0   0.963 
XDR   47   19.6   <0.001   43   0.5   0.536 
Strain familyc 
Non-R86   180   N/A   N/A   91   N/A   N/A 
R86 (Atypical)   58   7.8   <0.001   56   44.3   <0.001 
Resistance mutationc 
Other rpoB mutations   41   N/A   N/A   41   N/A   N/A 
rpoB S531L mutation   107   12.1   0.001   107   92.0   <0.001 
Legend to Table 4.1: 
Freq: Frequency of isolates showing a given characteristic included in the logistic regression analysis 
OR: Odds-ratio 
N/A: Not applicable  
DS: Drug-sensitive  
H mono: isoniazid mono-resistant  
Poly-R: poly-resistant but non-MDR 
R mono: rifampicin mono-resistant   
MDR s.s.: Multidrug-resistant sensu stricto (excluding identified pre-XDR and XDR isolates)  
a
Analysis adjusted for drug resistance group, strain family and rifampicin resistance mutation    
b
Mutations in rpoC were only present among rifampicin resistant isolates. Other drug resistance groups were 
therefore excluded from the analysis 
c
Only rifampicin-resistant isolates were included 
 
To further investigate the link between the rpoB S531L mutation and compensatory mutations in 
rpoC, we analyzed two previously published datasets; one from high-MDR-TB burden countries in 
Central Asia and one from a global collection of MDR M. tuberculosis isolates (40). Among isolates 
with an rpoB S531L mutation from these collections, 33.3% and 21.7% harboured rpoC mutations, 
respectively. Conversely, in only 4.3% and 2.3% of the isolates with other rpoB resistance mutations, 
respectively, rpoC mutations were detected. This association remained significant when adjusted for 
the different M. tuberculosis lineages in a multiple logistic regression analysis (p=0.001 and p=0.015 
for the high-burden and global dataset, respectively). The fact that we could observe the same 
association of rpoB S531L with rpoC mutations in three independent datasets supports a biological 







4.2. Investigation of the expression of energy metabolism genes in response to rifampicin 
exposure 
 
In the initial proteomic study, an increase in the abundance of proteins involved in energy metabolism 
(fixA, gltA2, opcA, lpdC, fba, atpA and atpH) were detected in two MDR clinical M. tuberculosis 
isolates after exposure to 2 µg/ml rifampicin (M Bester, MSc thesis, 2009). Subsequent transcriptomic 
analysis by QRT-PCR confirmed a significant up regulation of two genes (atpA and atpH) in response 
to rifampicin exposure. These two genes encode for catalytic subunits of the F1F0 ATP synthase 
enzyme (16). This enzyme is responsible for the production of ATP by the conversion of 
electrochemical potential energy generated by the proton motive force, into chemical energy in the 
form of ATP (57). The F1F0 ATP synthase enzyme is encoded by a ten gene atpBEFHAGDC operon 
together with Rv1303 and Rv1312, which is reported to be negatively regulated by Rv1846c (164). To 
test the hypothesis that M. tuberculosis increased its ATP production after rifampicin exposure, QRT-
PCR was done to determine whether the expression levels of the energy metabolism genes (previously 
identified,Chapter 3.2.3, Table 3.4), Rv1303, Rv1312 and Rv1846c were dependent on the genetic 
background of the strain, the level of rifampicin resistance and/or drug resistance profile. For this 
purpose isolates were selected from the Beijing and LCC lineage, displaying resistant profiles that 
varied from rifampicin-mono resistant to MDR (Chapter 3.2.1, Table 3.3).  
 
Significant differential gene expression of the majority of the genes irrespective of genetic 
background and drug resistance profiles was observed between isolates cultured in the presence of 2 
µg/ml rifampicin (Table 4.2). Four genes (atpA, atpH, fba and Rv1846c) displayed similar expression 
levels in all six isolates tested after rifampicin exposure. Of these atpA, atpH and fba showed 
significant up regulation (p<0.05, > 2 fold) while expression of Rv1846c remained constant. The 
remaining six genes (gltA2, fixA, opcA, Rv1303, Rv1312, lpdC) showed isolate specific gene 
expression with significant up regulation in at least one of genes in the isolates tested. Only one gene, 
gltA, showed significant down regulation in one of the rifampicin mono-resistant isolate after 
rifampicin exposure. 
 
Analysis of the rifampicin mono-resistant isolates showed that six genes (opcA, lpdC, fba, atpA, atpH 
and Rv1303) were significantly up regulated after rifampicin exposure. Additionally, three genes 
showed isolate specific gene expression, with the fixA significantly up regulated in the LCC isolate 
and gltA2 and Rv1312 significantly differentially expressed in the Beijing isolate.  
 
When separating the analysis in terms of rifampicin resistance levels in the MDR isolates, a distinct 
gene expression profile was observed between the high and low rifampicin MIC isolates. In the low 





exposure while in the high MIC MDR isolates and additional two genes were significantly up 
regulated (gltA and opcA). The Beijing and LCC high MIC strains also displayed strain specific 
significant up regulation for fixA and lpdC respectively.  
 





























fixA 4.13* -1.19 1.52 1.91 1.25 2.23* 
gltA2 3.64* -1.17 2.23* 1.16 -4.61# 1.36 
opcA 2.03* 1.37 2.12* 1.07 6.66* 2.23* 
lpdC -1.08 8.95* 2.55* 2.18* 5.26* 2.27* 
fba 2.12* 2.12* 2.04* 3.12* 2.38* 5.24* 
atpA 3.51* 2.00* 2.22* 4.07* 4.50* 2.04* 
atpH 2.62* 3.14* 4.12* 3.72* 2.76* 2.17* 
Rv1303 -1.18 1.16 1.22 1.16 2.86* 2.24* 
Rv1312 1.08 1.11 1.25 1.85 3.97* 1.02 
Rv1846c -1.16 -1.54 -1.99 -1.21 -1.92 -1.23 
Legend to Table 4.2: 
RIF: Rifampicin 
a
 Rifampicin MIC: 170 µg/ml, 
b
 Rifampicin MIC: 60 µg/ml, 
c
 Rifampicin MIC: 140 µg/ml, 
d
 Rifampicin MIC: 
30 µg/ml, 
e
 Rifampicin MIC: 70 µg/ml, 
f
 Rifampicin MIC: 80 µg/ml 
* Significant up regulation (and highlighted in grey) 
#
 Significant down regulation (and highlighted in blue) 
 
4.3. Selection and characterization of rifampicin resistant in vitro mutants 
 
Spontaneous in vitro mutants resistant to rifampicin were selected from a pan susceptible Beijing 
cluster 208 clinical isolate (K636) and a H37Rv laboratory strain of M. tuberculosis (Chapter 3.3) for 
subsequent genotypic and phenotypic characterisation (Chapter 3.3.3 and 3.3.4). In total 54 Beijing 
and 94 H37Rv rifampicin resistant mutants were selected from twenty and 100 7H10 Middlebrook 
plates containing 2µg/ml rifampicin, respectively. Targeted sequencing of the RRDR of the rpoB gene 
revealed that 52 of the 54 Beijing resistant mutants harboured mutations, while all 94 H37Rv resistant 
mutants harboured mutations in the RRDR of the rpoB gene (Appendix, Table A1 and A2). 
Altogether, nine mutations in the RRDR of the rpoB gene (Asp516Val, Ser522Leu, Ser522Trp, 
His526Asp, His526Arg, His526Tyr, Ser531Trp, Ser531Leu) (Figure 4.3) accounted for all mutations 
detected in the strains from the two different genetic backgrounds. The frequency of these mutations 
is shown in Figure 4.3, together with what was previously found by Huitric et al in Table 4.3 (82). 





mutants, with the amino acid change to aspartic acid being the most dominant (29.6%). Similarly, 
mutations at position 526 accounted for 69.1% of all mutations detected in the H37Rv resistant 
mutants, with the amino acid change to tyrosine being the most frequent (29.6%). In contrast, only 
18.5% and 13.8% of the Beijing and H37Rv resistant mutants harboured mutations at position 531 
respectively, while 11.1% and 15.97% harboured mutations at position 522, respectively. Only one 
H37Rv resistant mutant harboured a mutation (Asp to Val) at position 516.  Four Beijing resistant 
mutants harboured multiple mutations in the RRDR of rpoB, namely His526Arg/Ser531Trp, 
His526Asp/Ser531Leu, His526His/Pro/Asp/Tyr, His526His/Arg (Appendix, Table A1). These 
mutants might reflect a mixed population of single colonies. No significant statistical difference was 
observed for the frequencies of the different rpoB mutants selected from the two genetic backgrounds. 
However, the frequency of mutants selected from the H37Rv background harbouring the His526Asp, 
H526Arg, Ser531Leu and Ser522Trp mutations were significantly different from a previous study 
(82) (two sample proportion test, P < 0.05). Similarly, mutants selected from the Beijing background 
harbouring His526Asp and Ser522Trp mutations showed significant differences in their frequency 
when compared to a previous study (82) (two proportion test, P < 0.05).  
 
 
Figure 4.3: Frequency of rpoB mutations observed in in vitro mutants selected from a pan 





























Table 4.3: Frequency of rpoB mutations detected in in vitro mutants selected from a pan 
susceptible Beijing cluster 208 (K636) clinical isolate and the laboratory strain, H37Rv 
 
Frequency of rpoB mutations 
 
H37Rv Beijing 



















7 (13.0) 20 (22.4) 









Ser522Leu 5 (5.3) 13 (13) 2 (3.7) 12 (13.5) 
His526Pro 1 (1.1) 0 0 1 (1.12) 
Asp516Val 1 (1.1) 0 0 2 (2.25) 
Hi526Asp/Ser531Leu 0 0 1 (1.9) 0 
His526Arg/Ser531Trp 0 0 1 (1.9) 0 
His526His/Arg 0 0 1 (1.9) 0 
His526His/Pro/Asp/Tyr 0 0 1 (1.9) 0 
Wild type RRDR 0 0 2 (3.7) 0 
Legend for Table 4.3: 
* Reference: (82) 
a
 Significant difference in the frequency of respective rpoB mutation in the H37Rv background between current 
study and Huitric et al (highlighted in grey) 
b
 Significant difference in the frequency of respective rpoB mutation in the Beijing background between current 
study and Huitric et al (highlighted in blue) 
 
Since mutations at positions 531 and 526 in the rpoB gene are most frequently seen in clinical M. 
tuberculosis isolates (152), mutants harbouring mutations at these positions were selected for 
rifampicin MIC determination using the BACTEC MGIT 960 system. Additionally mutants selected 
from the H37Rv and harbouring mutations at position 522 were also subjected for MIC determination. 
The rifampicin MICs observed for the respective rpoB mutations are shown in Table 4.4. Rifampicin 
MICs were found to be highly variable among the Beijing and H37Rv mutants harbouring identical 
rpoB mutations. Mutants harbouring mutations at position 526 displayed higher rifampicin MIC 
values than the 531 mutants, with the majority of 526 mutants displayed rifampicin MICs that exceeds 
200 µg/ml. In contrast, mutants harbouring the Ser531Leu mutation showed MICs that varied 
between 60 and greater than 125 µg/ml, while mutants harbouring the Ser531Trp mutations displayed 
varying rifampicin between 100 µg/ml and greater than 200 µg/ml. Mutants harbouring the 
Ser522Leu mutation displayed rifampicin MICs lower or equal to 2 µg/ml, while mutants harbouring 
the Ser522Trp mutation displayed rifampicin MICs between 50 and 100 µg/ml. Varying levels of 
resistance also existed between the Beijing resistant mutants sharing identical rpoB and selected from 
a common progenitor. Together these results suggest that mechanisms other than the rpoB mutation 


















K636.53 26 >100 
K636.20 27 > 150 
K636.50 39 >150 
K636.36 44 >200 
H37Rv 
20 20 >200 
25 25 100 < x <150 
32 32 >200 
His526Tyr 
Beijing 
K636.21 2 >200 
K636.7 25 >200 
K636.24 25 >200 
K636.17 29 >200 
K636.40 39 >200 
K636.35 44 150 < x <200 
H37Rv 
3 3 >200 
6 6 >150 
27 27 >200 
76 76 >200 
91 91 >200 
92 92 >200 
His526Arg H37Rv 
16 16 >200 
28 28 >200 
34 34 >200 
36 36 >200 
70 70 150 < x< 200 
Ser531Leu 
Beijing 
K636.1 36 60 
K636.2 37 100 < x <150 
K636.44 37 >100 
K636.45 38 >125 
K636.3 42 80 
K636.48 42 50 
H37Rv 
17 17 >100 
30 30 100 < x <150 
67 67 100 < x < 200 
75 75 50 < x < 100 
Ser531Trp 
Beijing 
K636.43 25 >150 
K636.33 43 >100 
H37Rv 43 43 >200 
Ser522Leu H37Rv 
18 18 < 2 
26 26 2 
Ser522Trp H37Rv 
2 2 >50 
9 9 50 <x < 100 







4.4. Identification of genetic variants responsible for varying rifampicin resistance levels 
To identify genetic variants responsible for modulating the rifampicin resistance levels in M. 
tuberculosis the genomes of seven rifampicin resistant isolates were sequenced on the Illumina 
platform (Chapter 3.4, Table 3.8).  These seven genomes included strains from evolutionary distinct 
lineages, i.e. two in vitro selected rifampicin resistant clones from the  progenitor Beijing lineage 
strain  K636 (N37S1 and N36S1) and four clinical MDR isolates from the Beijing (R451, R439) and 
LCC lineages (R257, R179), respectively. 
 
4.4.1. Quality of raw reads and mapping coverage 
FastQC was used to generate a comprehensive quality control report for each of the genome 
sequences (Appendix, Figure A1-A6) that confirmed the quality and quantity of sequencing data. The 
quantity of these reads corresponded to an average coverage of 422 fold (341 - 477) for the seven 
genomes and GC content of the sequencing data ranged between 63 and 65% as expected for M. 
tuberculosis genomes (Table 4.5). A deterioration of the sequence quality of the reads was observed 
in the last 30 bp. Though a possibility would be those low-quality reads, we believed  that the depth 
and quality of the reads would be sufficient for mapping and SNP calling. The paired-end reads from 
each genome were aligned to H37Rv using BWA and Novoalign. Subsequently, the SAM Tools 
“flagstat” tool was used to calculate the mapping coverage of each aligner (Table 4.6). The percentage 
of reads mapping to the reference genome using Novoalign ranged between 62.53 and 83.07%, while 
BWA produced a mapping percentage of between 56.81 and 73.21%.  
 


















Rifampicin-mono (in vitro) 18541342 100 420.29 63 
N37S1 Rifampicin-mono (in vitro) 15080134 100 341.83 64 
K636 Pan susceptible 17310702 100 392.40 65 
R451 
LCC 
MDR 21166742 100 479.80 64 
R439 MDR 18533476 100 420.11 65 
R257 
Beijing 
MDR 18685916 100 423.57 64 












Table 4.6: Alignment statistics generated by SAM Tools for Novoalign and BWA  
















N36S1 18541342 13160743 (70.98) 12973790 (69.97) 18541342 12261205 (66.13) 
11329964 
(61.11) 
N37S1 15080134 9504621 (63.03) 9428962 (62.53) 15080134 9084970 (60.24) 
8566518 
(56.81) 
K636 17310702 14061826 (81.23) 13883056 (80.2) 17310702 13423591 (77.55) 
12673136 
(73.21) 
R451 21166742 16514674 (78.02) 16382912 (77.4) 21166742 15818582 (74.73) 
14996350 
(70.85) 
R439 18533476 14706215 (79.35) 14561646 (78.57) 18533476 14173632 (76.48) 
13419810 
(72.41) 
R257 18685916 14534376 (77.78) 14425222 (77.2) 18685916 13747583 (73.57) 
12919820 
(69.14) 
R179 21057802 17617283 (83.66) 17493194 (83.07) 21057802 17024433 (80.85) 
16227538 
(77.06) 
Legend to Table 4.6: * Total number of reads that passed quality control 
 
4.4.2. Variants identified using H37Rv as reference genome 
As described in chapter 3.4.4 and 3.4.5, different strategies were used to identify high confidence 
SNPs and indels for each genome against H37Rv as the reference genome. The number of SNPs and 
indels identified by each strategy for each genome is summarized in Table 4.7. SNPs and indels 
identified by the respective pipelines were then extracted for further analysis using Python scripts. A 
representation of the strategies followed to identify high confidence SNPs for each genome is shown 
in Figure 4.4. In comparison with H37Rv, the number of high confidence SNPs identified in the seven 
genomes ranged between 1065 and 1560, whereas the number of high confidence indels identified 
ranged between 93 and 166. The size of the short insertions and deletions ranged between 1 and 29 
base pairs.  
 





Beijing 208 Beijing 220 LCC DRF150 





BWA-GATK 6793 11462 11299 6236 6083 7285 8637 
BWA-SAM Tools 2189 3287 3396 2081 2315 1915 1845 
Overlapping BWA 1964 3029 3124 1908 2063 1778 1709 
Novoalign-GATK 1750 1716 1763 1878 1876 1216 1219 
Novoalign-SAM Tools 1724 1702 1684 1752 1875 1195 1192 
Overlapping Novoalign 1610 1585 1586 1649 1686 1129 1119 





BWA-GATK 327 334 330 360 301 289 287 
Novoalign-GATK 193 171 166 218 195 118 121 
Overlapping BWA-Novoalign* 147 139 140 166 148 93 96 






Figure 4.4: Representation of the strategies used to identify high confidence SNPs in one of the 7 
genomes (the in vitro mutant N36S1) 
 
Subsequently, Perl scripts were used to annotate the variants, categorise them according to cellular 
function and to predict the effect of the variants on protein level. Approximately 50 % of the SNPs 
were identified in the coding regions classified as conserved hypothetical proteins, cell wall and 
cellular processes, or intermediary metabolism and respiration (Table 4.8). The highest number of 
indels was identified in intergenic regions, as well as in genes classified to the PE-PPE family of 
proteins (Table 4.9). High confidence SNPs from each genomes were subsequently used for the 


















Table 4.8: SNPs identified in functional categories in all the M. tuberculosis isolates using 
H37Rv as reference genome 
  Beijing 208 Beijing 220 LCC DRF150 
  K636 (%) N36S1(%) N37S1(%) R179(%) R257(%) R451(%) R439(%) 
Cell wall and cell 
processes 
274 (17.9) 274 (17.9) 271 (17.7) 276 (17.7) 277 (17.2) 173 (16.2) 171 (16.1) 
Conserved 
hypothetical 
233 (15.2) 353 (15.3) 234 (15.3) 243 (15.6) 244 (15.2) 161 (15.1) 164 (15.4) 
Hypothetical 4 (0.3) 3 (0.2) 4 (0.3) 4 (0.3) 5 (0.3) 1 (0.1) 1 (0.1) 
Information 
pathways 
80 (5.2) 80 (5.2) 80 (5.2) 84 (5.38) 83 (5.2) 50 (4.7) 50 (4.7) 
Insertion seqs and 
phages 




273 (17.8) 271 (17.7) 272 (17.8) 282(18.07) 284 (17.7) 188 (17.6) 186 (17.5) 
Lipid metabolism 134 (8.7) 134 (8.8) 133 (8.7) 132 (8.46) 132 (8.2) 101 (9.5) 186 (17.5) 
PE/PPE families 208 (13.6) 208 (13.6) 204 (13.3) 210 (13.5) 241 (15.0) 177 (16.6) 98 (9.2) 




45 (2.9) 45 (2.9) 45 (2.9) 45(2.9) 49 (3.05) 32 (3.00) 29 (2.7) 
Intergenic 182 (11.9) 179 (11.7) 187 (12.2) 187 (12.0) 191 (11.9) 127 (11.9) 131 (12.3) 
Total 1533 1531 1530 1561 1608 1068 1065 
 
 
Table 4.9: Indels identified in functional categories in all M. tuberculosis isolates using H37Rv as 
reference genome 
  Beijing 208  
Beijing 220 LCC DRF150 
 
K636(%) N36S1(%) N37S1(%) R179(%) R257(%) R451(%) R439(%) 
Cell wall and cell 
processes 19 (12.9) 18 (13.0) 20 (14.3) 21 (12.7) 20 (13.5) 9 (9.7) 10 (10.4) 
Conserved hypothetical 21 (14.3) 20 (14.3) 21 (15.0) 28 (16.9) 22 (14.9) 14 (15.1) 14 (14.6) 
Hypothetical 2 (1.4) 2 (1.4) 2 (1.4) 2 (1.2) 2 (1.4) 1 (1.1) 1 (1.0) 
Information pathways 1 (0.7) 1 (0.7) 1 (0.7) 1 (0.6) 1 (0.7) 1 (1.1) 1 (1.0) 
Insertion seqs and 
phages 4 (2.7) 4 (2.9) 4 (2.9) 4 (2.4) 4 (2.7) 1 (1.1) 1 (1.0) 
Intermediary 
metabolism and 
respiration 11 (7.5) 12 (8.6) 12 (8.6) 11 (6.6) 12 (8.1) 13 (14.0) 13 (13.5) 
Lipid metabolism 8 (5.4) 8 (5.8) 8 (5.7) 11 (6.6) 9 (6.1) 4 (4.3) 6 (6.3) 
PE/PPE families 34 (23.1) 24 (17.3) 23 (16.4) 36 (21.7) 27 (18.2) 20 (21.5) 18 (18.8) 
Regulatory 5 (3.4) 6 (4.3) 6 (4.3) 9 (5.4) 8 (5.4) 1 (1.1) 1 (1.0) 
Virulence, 
detoxification and 
adaptation 4 (2.7) 5 (3.6) 4 (2.7) 4 (2.4) 4 (2.7) 0 (0.0) 0 (0.0) 
Intergenic 38 (25.8) 39 (28.1) 39 (27.9) 39 (23.5) 39 (26.3) 29 (31.2) 31 (32.3) 







Figure 4.5: Phylogenetic tree constructed by high confidence SNPs identified in all the isolates 
 
The above analysis implies that the observed variants were acquired in the LCC and Beijing isolates. 
This is however not the case as H37Rv is not the progenitor of these two lineages. In order to identify 
SNPs unique to the Beijing or LCC lineage, high confidence SNPs present in all seven genomes were 
extracted from the high confidence SNPs files. The 539 SNPs present in all Beijing and LCC isolates 
represents changes that occurred in H37Rv (Figure 4.6). A total of 850 SNPs were found to be unique 
to members of the Beijing lineage, while 485 SNPs were found to be unique to members of the LCC 
lineage. Functional categorization of these SNPs revealed that the highest proportion of SNPs to the 
total number of genes in each functional class was identified in PE-PPE genes (Table 4.10). 
Thereafter, SNPs in lipid metabolism play a significant role in the adaptation of the pathogen, which 
may reflect different levels of pathogenicity for the members of the three lineages. Similarly, genes 
functionally classified in information pathways and cell wall and cell processes was also shown to be 
under evolutionary pressure. 
 
 





















Cell wall and cell processes 773 97 (12.5) 148 (19.1) 69 (8.9) 
Conserved hypothetical 1031 86 (8.3) 132 (12.8) 74 (7.2) 
Hypothetical 16 1 (6.3) 2 (12.5) 0 (0.0) 
Information pathways 242 30 (12.4) 47 (19.5) 20 (8.3) 
Insertion seqs and phages 147 9 (6.1) 28 (19.04) 20 (13.6) 
Intermediatry metabolism and respiration 936 92 (9.8) 154 (16.5) 92 (9.8) 
Lipid metabolism 271 55 (20.3) 67 (24.7) 41 (15.1) 
PE-PPE 168 69 (41.1) 113 (67.3) 83 (49.4) 
Regulatory 198 20 (10.1) 32 (16.2) 9 (4.5) 
Virulence, detoxification and adaptation 238 16 (6.7) 26 (10.9) 14 (5.9) 
Total 4020 539 850 485 
Legend to Table 4.10: 
a Number of genes belonging to each functional category in M. tuberculosis 
* Proportion of SNPs to the total number of genes classified to each functional category 
 
4.4.3. Comparative analysis of the high confidence variants between genomes 
Python scripts were used to compare the high confidence variants between the different genomes and 
GenomeView was used to eliminate false positives. Due to the high GC content found in transposable 
and repetitive elements (i.e.  PE-PPE/PGRS and IS6110), reads containing these elements are difficult 
to map to the reference genome. Therefore variants identified in these regions were excluded from 
further analysis since these regions are high GC rich. 
 
4.4.3.1. Increased rifampicin resistance acquired in in vitro selected mutants 
To identify genetic variants which might result in increased level of rifampicin resistance acquired in 
vitro, the genomes of two in vitro selected rifampicin resistant mutants (N36S1, N37S1) and its 
Beijing pan susceptible progenitor (K636) were compared. Only one SNP in addition to the rpoB 
S531L mutation was identified to be unique to the genome of N36S1, after comparing the high 
confidence variants (relative to H37Rv) identified in the genomes of N36S1 (rifampicin MIC: 60 
µg/ml) and K636 (Table 4.11). This synonymous SNP was identified in a conserved hypothetical 
protein encoded by TB16.3. One deletion in glpK, encoding for a glycerol kinase, was identified to be 
unique to N36S1. This deletion causes a frame shift which will result in a premature stop codon 
(Table 4.12). 
 
Two SNPs in addition to the rpoB S531L were identified to be unique to the genome of N37S1, after 
comparing the high confidence variants (relative to H37Rv) identified in the genomes of N37S1 
(rifampicin MIC: > 100 µg/ml) and K636 (Table 4.11). Two of these SNPs were identified in genes 





glycogen degradation. Similar to the genome of N36S1, the deletion at position 573 in glpK was also 
identified in the genome of N37S1 (Table 4.12). 
 





change Gene description 
Functional 
Group 
SNP present in: 
N36S1 N37S1 



















Legend for Table 4.11: 
* Amino acid change according to M. tuberculosis gene sequence. Would translate to S531L according to the E. 
coli gene sequence 
 
Table 4.12:  Indels found to be unique to the genomes of the in vitro mutants N36S1 and N37S1 
Locus Gene 
Position 









Rv3696c glpK 573 C 
(deletion) 







Legend for Table 4.12: 
WT = wild type 
MUT = mutant 
ORF = open reading frame 
 
Variants identified unique to the in vitro rifampicin resistant mutants were validated by targeted DNA 
sequencing of the two mutants and the pan susceptible progenitor isolate. PCR amplification and 
Sanger sequencing confirmed the presence of the SNP in TB16.3 in both mutants (N37S1 and N36S1) 
the SNP in malQ in N37S1. The deletion identified in glpK in both mutant genomes was also present 
in the progenitor isolate, K636, and therefore was excluded as a candidate responsible for modulating 
rifampicin resistance levels. The SNPs in malQ and TB16.3 were screened in the remaining panel of 
52 in vitro rifampicin resistant mutants and their progenitor culture (Section 3.3.2.2) before rifampicin 
selection (Appendix Table A1). The V407V change in malQ was identified in only one additional 
mutant, K636.44 (rifampicin MIC > 100 µg/ml). This mutant shares the same progenitor before 
rifampicin selection as N37S1. The G101G SNP in TB16.3 was identified in 20 of the 52 mutants 
screened. These 20 mutants represented 10 of the 20 progenitors before rifampicin selection. An 
additional four progenitors also harboured this SNP, while the mutants selected from these 
progenitors harboured the wild type nucleotide.  This suggested that the progenitors before rifampicin 






4.4.3.2. Increased rifampicin resistance acquired in vivo in Beijing strain background 
To identify genetic variants which might result in increased rifampicin resistance acquired in vivo, the 
high confidence variants (relative to H37Rv) identified in the two closely related Beijing clinical 
isolates, R179 (Rifampicin MIC: 140 µg/ml) and R257 (Rifampicin MIC: 30 µg/ml), were compared. 
In total, five non-synonymous and four synonymous SNPs were unique to the isolate with the high 
rifampicin MIC isolate R179 (Table 4.13). Of the five non-synonymous SNPs, three were identified in 
genes known to confer drug resistance in M. tuberculosis, namely rpoB (additional to the 
rpoBS531L), rpsL, ethA. The two remaining non-synonymous SNPs were identified in lpqN and 
Rv3108, which encodes for a lipoprotein and hypothetical protein respectively. Additionally, four 
Indels were identified unique to the genome of R179 (Table 4.14). All four indels were identified in 
non-essential genes (170) involved in various cellular functions including lipid metabolism (echA), 
regulation (mprA) and those with unknown function (Rv2449c, Rv3195). Only one of the four indels 
(one base pair deletion in mprA) would result in a frame shift and premature stop codon. 
 





change Gene description Functional Group 
Rv0583c lpqN G235A Asp7Asn Lipoprotein Cell wall and cell processes 
Rv0667 rpoB C1147T Pro483Ser DNA-directed RNA 
polymerase beta chain 
Information pathways 
Rv0682 rpsL A128G Lys43Arg 30S ribosomal protein S12 Information pathways 
Rv1057   G21A Arg7Arg Conserved hypothetical 
protein 
Conserved hypothetical 
Rv2850c   C1044T Asp348Asp Magnesium chelatase Intermediary metabolism and 
respiration 
Rv2946c pks1 C1134G Pro378Pro Polyketide synthase Lipid metabolism 
Rv3108   A245G Asp82Gly Hypothetical protein Conserved hypothetical 
Rv3546 fadA5 G681C Gly227Gly Acetyl-CoA 
acetyltransferase 
Lipid metabolism 
Rv3854c ethA T409C C137Arg Monooxygenase Intermediary metabolism and 
respiration 
Legend to Table 4.13:  













Table 4.14: Indels found to be unique to the genome of R179  
Locus Gene 
Position 

















































Legend for Table 4.14: 
WT = wild type 
MUT = mutant 
ORF = open reading frame 
 
To identify genetic variants which might result in decreased level of rifampicin resistance acquired in 
vivo, variants identified unique to the genome of the low rifampicin MIC isolate of R257 was also 
investigated (Table 4.15). From the nine SNPs identified as unique to low MIC isolate R257, six were 
non-synonomous and involved in various cellular functions including information pathways (rpoC), 
virulence, detoxification and adaptation (katG, mce3F), intermediary metabolism and respiration 
(moeB2) and those with unknown function (Rv0311). In addition, two Indels (Table 4.16) unique to 
the genome of R257 were identified in non-essential genes ethA and pncA involved in intermediary 
metabolism and respiration (170). Mutations in these two genes are known for conferring resistance to 
anti-TB drugs ethionamide and pyrazinamide. 
 




Amino acid change Gene function Functional Group 
Rv0169 mce1A G183A Gly61Gly MCE-family protein Virulence, detoxification 
and adaptation 
Rv0311  T83C Ile28Thr Hypothetical protein Conserved hypothetical 
Rv0668 rpoC T1450G Trp484Gly DNA-directed RNA 
polymerase beta chain 
Information pathways 
Rv0823c  C960T Leu320Leu Transcriptional regulator Regulatory 
Rv1046c  G59A Arg20His Hypothetical protein Hypothetical 
1472359* Intergenic A/C- - - - 




Rv1971 mce3F C686A Ala229Glu MCE-family protein Virulence, detoxification 
and adaptation 




Legend to Table 4.15: 
Non-synonymous SNPs are highlighted in grey   





























Rv3854c ethA 66 T (deletion) Truncated 
protein 




Legend for Table 4.16: 
WT = wild type 
MUT = mutant 
ORF = open reading frame 
 
4.4.3.3. Increased rifampicin resistance acquired in vivo in LCC strain background 
To identify genetic variants which might result in increased rifampicin resistance acquired in vivo, the 
high confidence variants (relative to H37Rv) identified in the two closely related LCC clinical 
isolates, R451 (Rifampicin MIC: 170 µg/ml) and R439 (Rifampicin MIC: 60 µg/ml) were compared. 
In total, seven non-synonymous and three synonymous SNPs were identified to be unique to the 
genome of high MIC isolate R451 (Table 4.17). The seven non-synonymous SNPs were in genes 
involved in various processes including cell wall and cell processes (Rv0283, lpqQ, Rv1081c, 
Rv1226c); lipid metabolism (omt); virulence, detoxification and adaptation (cstA) and intermediary 
metabolism and respiration (icd1). Additionally, two intragenic Indels and one intergenic indel were 
unique to the genome of R451 (Table 4.18).  The Indels identified in ndhA and FadD12 results in a 
frameshift and premature stop codon. NdhA is annotated as a Membrane NADH dehydrogenase 
involved in intermediary metabolism and respiration, while FadD12 is annotated as a Long-chain 


























Gene function Functional Group 
Rv0283  G67A Val23Ile Conserved membrane protein Cell wall and cell processes 
Rv0440 groEL G1350A Gln450Gln 60 kda chaperonin 2 groEL2 Virulence, detoxification and 
adaptation 
Rv0787  C270A Ala90Ala Hypothetical protein Conserved hypothetical 
Rv0835 lpqQ A485G Asp162Gly Lipoprotein Cell wall and cell processes 
Rv1081c  C237A Asp79Glu Conserved membrane protein Cell wall and cell processes 
Rv1153c omt T467C Val156Ala O-methyltransferase Lipid metabolism 
Rv1226c  C247T Arg83Trp Transmembrane protein Cell wall and cell processes 
Rv2236c cobD G882A Arg294Arg Cobalamin biosynthesis 
transmembrane protein 
Intermediary metabolism and 
respiration 
Rv2289 cdh C426T Asn142Asn cdp-diacylglycerol 
pyrophosphatase 
Lipid metabolism 
Rv3063 cstA G472T Gly158Cys Carbon starvation protein A Virulence, detoxification and 
adaptation 
Rv3339c icd1 G607A Gly203Ser Isocitrate dehydrogenase Intermediary metabolism and 
respiration 
Legend to Table 4.17:  
Non-synonymous SNPs are highlighted in grey   
 
Table 4.18: Indels found to be unique to the genome of R451 
Locus Gene 
Position 






















- - - - - 














Legend for Table 4.18: 
WT = wild type 
MUT = mutant 
ORF = open reading frame 
 
To identify genetic variants which might result in decreased rifampicin resistance acquired in vivo, 
variants identified to be unique to the genome of R439 was also investigated (Table 4.19). Only four 
SNPs were identified to be unique to the genome of R439, from which only two were identified as 
non-synonymous. These two SNPs were identified in Rv0284 and far, encoding for proteins involved 
in cell wall and cell processes and lipid metabolism respectively. Additionally two Indels were also 
unique to the genome of R439 (Table 4.20). These two Indels were in the plsB2 and plsC genes which 













Gene function Functional Group 
Rv0284  T581G Leu194Arg Conserved membrane protein Cell wall and cell processes 
Rv0855 far C802A Arg286Ser Fatty-acid-CoA racemase Lipid metabolism 
Rv2623 TB31.7 C504G Gly168Gly Conserved hypothetical protein Virulence, detoxification and 
adaptation 





Legend to Table 4.19:  
Non-synonymous SNPs are highlighted in grey   
 










Rv2482c plsB2 1119 CT 
(deletion) 




















Legend for Table 4.20: 
WT = wild type 
MUT = mutant 





























5.1. Epidemiological relevance of compensatory mutations in rpoA/C 
Several recent studies established the role of compensatory mutations in the genes rpoA and rpoC to 
alleviate the fitness-cost incurred by rifampicin resistance-conferring mutations in rpoB. However, as 
yet, little is known about the epidemiological relevance of compensatory evolution in drug-resistant 
M. tuberculosis. This study is the first to show that putative compensatory mutations in rpoC are 
prevalent among rifampicin-resistant isolates in a high-burden setting in South Africa, and strongly 
associated with transmission of rifampicin-resistant strains. Moreover, the presented data confirms the 
convergent evolution of specific putative compensatory rpoC mutations, which is consistent with 
positive selection of these mutations as shown previously (40). Taken together, our findings suggest 
that compensatory evolution in M. tuberculosis is of epidemiological relevance and contributes to the 
spread of drug resistance.  
 
This study has several limitations. The sample analyzed consists of a convenience sample which does 
not accurately represent the overall population structure of M. tuberculosis in this setting. Thus, the 
true proportions of M. tuberculosis isolates with rpoC mutations may deviate from the proportions 
herein reported. However, these limitations do not affect the main conclusions of this study. 
Furthermore, defining transmission chains on the basis of identical IS6110 RFLP patterns is not ideal. 
For example, two of the five isolates showing non-clustered RFLP types belonged to the R86 
genotype, as suggested by other phylogenetic markers (Appendix, Table A3). Thus, rather than being 
rarely transmitted, these strains are representative of new RFLP variants, which emerged from a fast-
spreading clone of M. tuberculosis, herein identified to be associated with rpoC mutations. Similarly, 
the remaining isolates with non-clustered RFLP patterns harbouring rpoC mutations also belonged to 
well-recognized strain families. Thus, this study probably overestimates the proportion of putative 
compensatory mutations among relatively infrequently transmitted strains. 
 
Multivariate logistic regression analysis revealed a strong association between the presence of rpoC 
mutations and strain genotype (OR=44.3; p<0.001) as well as the specific rifampicin resistance 
mutation acquired (OR=92.0; p<0.001) (Table 4.1). The observation that the variability in terms of the 
presence of rpoC mutations is critically influenced by purely genetic properties, perhaps illustrates 
how the direction of compensatory evolution is shaped by epistatic interactions with the strain genetic 
background. Indeed, studies in several bacterial species have shown how genetic background and 
primary drug resistance mutations predetermine subsequently acquired mutations, favoured within a 
particular strain background (172, 185, 212, 213). 
 
The association between the rpoB S531L and rpoC mutations could be explained by at least three 
models. Firstly, compensatory mutations in rpoC could act by restoring structural interactions 





mutation in rpoB. In this scenario, resistance mutations other than the rpoB S531L mutation could 
affect the structural properties of the RNA polymerase complex in different ways, such that mutations 
in rpoC are not able to restore the interaction between β‟- and β-subunits. This could explain the 
relative underrepresentation of rpoC mutations in strains harbouring such mutations. In Salmonella 
enterica distinct mutations in rpoC have been shown to compensate for the rpoB R529C mutation 
(28). Secondly, the rpoB S531L mutation may allow for a wider range of compensatory mutations, 
including mutations in rpoC, while other rifampicin resistance mutations could require more specific 
adaptations outside the genetic regions herein investigated. This is supported by the variety of 
compensatory mutations detected among strains with an rpoB S531L mutation. Finally, rpoB S531L 
has been shown to cause a small fitness defect compared to other rpoB mutations (63). Hence, such a 
low fitness cost might be easier to compensate than other rifampicin resistance mutations. More work 
is required to differentiate between these various hypotheses. 
 
5.2. Investigation of the expression of energy metabolism genes in response to rifampicin 
exposure 
 
This is the first study to investigate the expression levels of energy metabolism genes in rifampicin 
resistant clinical isolates of M. tuberculosis in response to rifampicin exposure. While the majority of 
genes showed significant differential expression after rifampicin exposure, three genes (atpH, atpA 
and fba) were found to be up regulated irrespective of genetic background of the strain, degree of drug 
resistance or level rifampicin resistance (MIC). Interestingly, the expression levels of Rv1303 and 
Rv1312 were not responsive to rifampicin despite up regulation of other genes in the operon (atpA and 
atpH) This suggests either the existence of an internal promoter within the operon which 
independently regulates expression of the atpBEFHAGDC genes or that Rv1303 and Rv1312 RNA is 
rapidly degraded within the cell (short half-life).  
 
Our observation of the absence of a change in the expression level of Rv1846c is counterintuitive 
given that previous studies have concluded that this gene encodes a protein which acts as a negative 
regulator of the atpBEFHAGDC operon. The absence of repression may be explained by an increase 
in the rate at which Rv1846c was cleaved thereby preventing binding to the promoter region of the 
operon. However, the expression level of the gene Rv1255c responsible for cleavage of Rv1846c was 
not tested in this study (Chip-seq data, www.tbdb.org). In this study we also showed that expression 
of fba was up regulated in response to rifampicin. fba encodes for the fructose-biphosphate aldolase, a 
key enzyme in glycolysis (169), suggesting an increased production of ATP through this pathway as 
well. It is predicted that an investigation of other genes involved in glycolysis might reveal whether a 






In this study we observed a clear distinction between the expression levels of the selected genes 
between the high and low rifampicin MIC strains. The overall increase in expression levels in the high 
MIC strains suggests that these strains have a higher energy requirement and thus have adapted their 
transcriptional response to increase energy production. Two genes, gltA and opcA, displayed 
significant up regulation in both high MIC MDR isolates, while no significant change observed for 
these genes in the low MIC MDR isolates. GltA2 encodes for the citrate synthase enzymes, which is 
the pace-making enzyme of the Citric acid cycle, which involves a series of chemical reactions 
essential for energy production through aerobic respiration (83). OpcA encodes for a protein essential 
for the assembly of the glucose-6-phosphate dehydrogenase (203). This enzyme is the rate limiting 
enzyme in the pentose phosphate pathway, which is an alternative pathway to glycolysis for the 
production of energy from glucose-6-phospate (79). We hypothesise that the up regulation of both 
these rate limiting enzymes of the Citric acid cycle and pentose phosphate pathway in the high 
rifampicin MIC isolates would result in increased rate of the production of ATP. 
 
The expression profiles between the MDR and mono-rifampicin resistant isolates were vastly 
different, with more genes being significantly up regulated in both mono-rifampicin resistant isolates. 
This may suggest that the energy requirements of M. tuberculosis adjust with the acquisition of 
additional drug resistance causing mutations. However, the effect of these mutations regarding energy 
metabolism remains unknown.  
 
The overall observation of increased expression of energy metabolism genes supports our hypothesis 
that rifampicin resistant isolates, when exposed to rifampicin, have increased energy requirements.  
The recently reported up regulation of ATP dependent efflux and transporter genes in response to 
rifampicin in the same MDR isolates suggests that these metabolic processes are linked (114). These 
findings suggest that rifampicin resistant bacilli are responding to the presence of rifampicin by 
increasing efflux in an energy dependent manner and thereby maintaining the intracellular 
concentration of rifampicin below a toxic threshold.  This may have important ramification for the TB 
treatment guidelines as we have shown that inappropriate treatment of MDR-TB with rifampicin 
induced cross-resistance to second-line anti-TB drugs (114).  
 
The observation that certain environmental stimuli leads to the elevation of ATP dependent efflux 
activity provides a platform to propose a hypothesis to explain the increased rate in culture conversion 
of MDR-TB patients who were treated with a standardized second-line anti-TB drug regimen in 
combination with the promising new drug TMC207 relative to those only receiving the standardized 
regimen. TMC207 inhibits ATP synthesis by binding to the AtpE subunit of the mycobacterial F1F0 
ATP synthase (14, 99). We propose that inhibition of ATP synthesis will deprive the efflux pumps 





intracellular concentration of toxic compounds. Consequently, there will be an accumulation of 
second-line anti-TB drugs with the bacilli leading to more efficient binding of the drugs to their 
targets and cell death.  
 
5.3. Selection and characterization of rifampicin resistant in vitro mutants 
 
Several studies have investigated the frequency of mutations in the RRDR of rpoB in in vitro 
rifampicin resistant mutants and although the level of rifampicin resistance was investigated in these 
mutants, it was not clear what the contribution of the rpoB mutation to the level of rifampicin 
resistance (82, 120). Here we aimed to characterize the frequency of rpoB mutations in in vitro 
mutants selected from two distinct M. tuberculosis genetic backgrounds. Secondly, we also aimed to 
characterize the rifampicin resistance phenotype of these mutants by investigating the level of 
rifampicin resistance. 
 
Previous studies have shown that the Ser531Leu and His526Tyr mutations in rpoB occur at the 
highest frequency among in vitro generated rifampicin resistant mutants. In addition, these studies 
have inferred that these two mutations are associated with the lowest fitness cost in in vitro resistant 
mutants (63) and therefore a possible correlation between the mutation frequency and fitness cost can 
be made. In this study mutations at amino acid position 526 were found to be overrepresented in both 
genetic backgrounds, with the frequency of the His526Asp mutant significantly different from what 
was observed in a previous study (82). Mutants selected from the H37Rv background showed also 
significant differences in frequency for three additional mutations (His526Arg, Ser531Leu and 
Ser522Trp), while mutants selected from the Beijing background only showed significant differences 
in frequency for one additional mutation (Ser522Trp). We therefore suggest that the laboratory 
conditions and strain genetic backgrounds used in this setting affected the type and frequency of 
mutants selected.  
 
Mutations at amino acid position 526 in the rpoB also displayed higher levels of resistance above 200 
µg/ml with less variability in both genetic backgrounds. In contrast, mutations at amino acid position 
531 showed higher variability between 50 and 150 µg/ml in the Beijing background, whereas mutants 
selected from the H37Rv harbouring 531 mutations showed less variability, with rifampicin MICs 
remaining ranging between 100 and 200 µg/ml. These results suggest that the rpoB mutation alone 








5.4. Identification of genetic variants responsible for varying rifampicin resistance levels 
 
This is the first study to investigate genomic variation and its association with varying rifampicin 
resistance levels in closely related M. tuberculosis isolates. M. tuberculosis strains can be divided into 
three principles genetic groups (PGG) based on polymorphisms found at position 463 in katG and 
position 95 in gyrA, with the Beijing lineage belonging to PGG 1, LCC to PGG 2 and H37Rv to PGG 
3 (187). Our analysis of whole genome sequencing data from seven M. tuberculosis isolates, 
identified on average 1552 high confidence SNPs and 148 high confidence indels in Beijing isolates 
when compared to the reference genome, H37Rv. Similarly, the comparison between H37Rv and the 
LCC isolates identified an average of 1066 SNPs and 94 indels. A total number of 850 and 485 of all 
SNPs identified relative to H37Rv were found to be unique to the Beijing and LCC lineages, 
respectively. Additionally, 539 SNPs were unique genetic changes acquired in the genome of H37Rv. 
This highlights the importance knowing the evolutionary direction when using H37Rv as the 
assembly template. Furthermore, it must be noted that when using this method of assembly then 
certain genetic information will be lost which includes IS6110 insertion positions and regions absent 
in H37Rv. 
 
Analysis of the SNPs unique to the respective lineages showed that the highest number of SNPs (as a 
proportional of the number of genes classified to each functional category (http://tuberculist.epfl.ch/)), 
were localized in PE-PPE genes. These genes account for approximately 10% of the M. tuberculosis 
genome and are known to be highly polymorphic and hypothesized to be involved in antigenic 
variation (29, 97). More recently, numerous other functions have been assigned to this family of 
proteins including virulence and modulation of the host immune response as well as hydrolase activity 
(6, 136, 137, 200). In addition this analysis in this study showed that changes in genes involved in 
lipid metabolism, information pathways and cell wall and cellular processes play a predominant role 
in the evolutionary adaptation of this pathogen. This suggests that these cellular processes are under 
evolutionary pressure which may explain phenotypic differences observed between the clinical 
strains.  
 
In order to identify genetic variants responsible for increasing rifampicin resistance in the in vitro 
resistant M. tuberculosis mutants, the genomes of two in vitro selected rifampicin resistant mutants 
and their progenitor pan susceptible Beijing isolate were compared. After excluding variants 
identified in repetitive and transposable regions, only two synonymous SNPs and one deletion were 
acquired in addition to the rpoB Ser531Leu mutation in the mutant genomes. The functional relevance 
of the two SNPs in TB16.3 and malQ remains unclear, as they do not alter the protein structures. The 
low frequency of the Val407Val SNP in malQ in the remaining set of the in vitro rifampicin resistant 





resistance levels. In contrast the Gly101Gly SNP in TB16.3 was identified in 38% (20/54) which 
represented 70% (14/20) of the progenitors before rifampicin selection. Three scenarios could explain 
the occurrence of this SNP in multiple in vitro mutants harbouring different rpoB mutations and 
rifampicin resistance levels. Firstly, it is possible that this genetic event arose convergently in 14 of 
the 20 pre-rifampicin selected progenitors, which would suggest the importance of this SNP under the 
specific selection pressure. Secondly, it is also possible that this SNP was acquired randomly with a 
minimal fitness cost during the first culturing step of the Luria-Delbrück fluctuation assay. In the 
latter case, this SNP would not be associated with the evolution of rifampicin resistance. Thirdly, the 
possibility also exist that this variant was present in a proportion of the progenitor population. 
 
Currently, we do not understand the effect of synonymous SNPs on the regulation of cellular 
processes and homeostasis of the cell. While synonymous SNPs are known to effect mRNA stability, 
mRNA processing, mRNA maturation and substrate specificity, thereby altering gene expression and 
protein function in mammalian cells, little is known about the effect of these SNPs in Mycobacteria 
(33, 52, 91, 96, 128). It is also suggested that SNPs could affect the binding sites of small regulatory 
RNAs, thereby affecting the gene expression of the target (64, 141). The limited number of variants 
identified in this study might suggest that increased rifampicin resistance in vitro might be due to non-
genetic (epigenetic) regulatory mechanisms. However, it is acknowledged that the genome sequencing 
methodologies used in this study have certain limitations; a) mutations in regions absent in H37Rv 
would not be identified, b) repetitive regions (such as the PE-PPE protein families) are not fully 
represented, and c) the impact of transposon elements was not assessed. In particular, the gene 
sequences of the PE-PPE protein families have been shown with Sanger sequencing to be highly 
polymorphic (123, 214). There is increasing evidence that these proteins may modulate the structure 
of the cell wall and thereby may influence permeability towards certain drugs (46, 165).  
 
This study showed that high genomic diversity exists between isolates previously termed "closely 
related" based on IS6110 RFLP type and targeted DNA sequencing of genes conferring drug 
resistance. In total 25 variants differentiated the two MDR Beijing isolates, whereas 20 variants 
differentiated the MDR LCC isolates. A previous study showed through with whole genome 
sequencing that two clinical isolates sharing identical IS6110 RFLP fingerprints are different at 131 
separate loci (142). That study raised the question to whether standard typing measures are of 
sufficient discriminatory power to differentiate between strains, which might result in 
misinterpretation of the transmission dynamics of M. tuberculosis outbreaks. Thus the difference in 
the levels of rifampicin resistance in our study may reflect the accumulation of a number of different 






In summary, the LCC genomes showed that 61.43% (10/14) of the variants (non-synonymous SNP 
and indels) were identified in genes involved in cell wall and cell processes and lipid metabolism. We 
therefore propose that structural and integrity differences in the cell wall caused by these variants 
might influence rifampicin resistance levels. A recent study have shown the presence of potential 
adapting mutations in genes related to cell wall biosynthesis in clinical drug resistant isolates (201). 
Structural changes in proteins involved in lipid metabolism might result in increased energy 
production through the catabolism of host lipids or increased production (anabolism) of lipids 
reincorporated into the lipid rich cell wall. Structural modulation of the cell wall might influence the 
permeability towards certain drugs, whereas increased production of ATP can be utilized by other 
cellular processes such as efflux systems to modulate levels of resistance. In contrast, the Beijing 
genomes showed less variability in these cellular processes (2/17, 11.77%) and instead showed higher 
variability in the genes conferring drug resistance or compensatory mechanisms, with 41.18% (7/17) 
of the variants (non-synonymous SNPs and Indels) identified in rpoB, rpsL, ethA, pncA, rpoC and 
katG. From these seven variants, three have been previously reported, with the SNP in rpsL known to 
confer streptomycin resistance (135). Non-synonymous SNPs in rpoC have also been described as a 
putative compensatory mechanism for rifampicin resistance (40). Mutations at position 564 in rpoB 
(as identified in R257 ) outside of the RRDR have also previously been reported, albeit with the 
amino acid change from proline to leucine (74). The clinical isolate harbouring this mutation also 
harboured a rpoB Glu562Gly mutation and displayed a rifampicin MIC below 1 µg/ml (74). It has 
also been shown in S. enterica that the acquisition of the rpoB Pro564Ser mutation in addition to the 
Arg526Cys mutation resulted in decreased rifampicin resistance (two fold) and increased growth 
fitness (measured as the doubling time) (28).  
 
The findings from the MDR isolates are in conflict with previous results which showed that 
rifampicin stimulated the expression of efflux pump and transporter genes (114). However, no 
association between specific transporters/pumps and high rifampicin resistance levels could be made. 
Despite this, it would be envisaged that a genetic component for increased efflux expression would be 
present. Our failure to identify such a mechanism could be due to the limitations associated with the 
study (see above and below). An alternative explanation could be that the rpoB mutation affects the 
functionality of the RNA polymerase by changing the promoter specificity and in so doing alters the 
transcriptome. This notion is supported by the observation that rifampicin mono-resistant M. 
tuberculosis isolates harbouring mutations at codon 526 displayed delayed induction of efflux 
mechanisms after rifampicin exposure compared to isolates harbouring mutations at codon 531 (114).  
 
From these results it is evident that the genetic component for increased rifampicin resistance is more 
complex than previously thought with no clear pathway employed by the bacteria to survive in higher 





seen in the MDR isolates) on the mutations identified remains unknown. A further confounding factor 
is that whole genome sequencing of the MDR isolates were done from a representative scrape of the 
total population of bacterial cells which may include sub-populations with varying rifampicin 
resistance levels. Thus the MIC determination may not reflect the true population structure as only 
clones with the highest level of resistance within the culture will be measured. This implies that the 
genetic variants observed may not reflect the sub-population with the highest MIC as all genetic 
variants with confidence levels of <95% will have been excluded from the analysis. Therefore, we 
suggest that future studies using whole genome sequencing should be done on single colony forming 
units to exclude heterogeneity represented by the mixed bacterial population. In addition, the 
combined use of the four different strategies for the analysis of whole genome sequence data would 
minimize the identification of false positives. Furthermore, future studies should include functional 
analysis of the variants; however, experimental planning will be limited by the prediction of the 
number and order in which these variants were acquired by M. tuberculosis. 
 
Finally, this study only investigated varying levels of rifampicin resistance in isolates harbouring the 
rpoB Ser531Leu mutation. The question remains whether similar modulatory mechanisms are used by 
isolates harbouring mutations at different loci in the RRDR, and why certain mutations (i.e. at 





























Despite the availability of effective anti-TB drugs, TB still remains an urgent global health problem 
(236). This is in part due to the emergence of spontaneous drug resistance by M. tuberculosis which is 
driven by several factors such as delayed diagnosis, the use of low quality drugs, malabsorption and 
inappropriate treatment (69, 93). While the acquisition of drug resistance is usually associated with a 
fitness cost, M tuberculosis has displayed the ability to adapt its genome to compensate for this loss 
(62). Therefore, the complexity of rifampicin resistance extends beyond the acquisition of mutations 
in rpoB and previous studies have suggested that mutations in rpoC ameliorate the fitness cost 
inferred by the rpoB mutations. This is the first study to investigate the prevalence of putative 
compensatory rpoC mutations in drug resistant clinical isolates from high TB burden settings in South 
Africa. This study also aimed to investigate whether mutations in rpoC has an epidemiological impact 
on the transmission of drug resistant M. tuberculosis clinical isolates. Results from this study 
demonstrated that mutations in rpoC are strongly associated with transmission of rifampicin-resistant 
strains in this setting. We therefore postulate that rpoC mutations facilitate the restoration of fitness in 
some clinical strains of drug-resistant M. tuberculosis, thereby enhancing their ability to spread. The 
fact that not all successful MDR/XDR strains carry such mutations suggests that alternative 
mechanisms of fitness compensation might exist. The observation of an association between strain 
genotype as well as the rpoB S531L mutation with rpoC mutations supports a role for mutation-
specific epistatic effects in driving the compensatory events described in this study.  
 
The complexity of rifampicin resistance is further inferred by M. tuberculosis displaying varying 
levels of rifampicin resistance in clinical isolates with identical rpoB mutations (82, 114). This 
suggests that other mechanisms in addition to rpoB mutations are responsible for the modulation of 
rifampicin resistance. Recently it was also demonstrated that the level of resistance can be lowered by 
the inclusion of efflux pump inhibitors, suggesting efflux and transporter mechanisms as strong 
candidates for the modulation of the intra-cellular concentration of rifampicin (114). A previous study 
done in our group also showed increased expression of proteins involved in the production of energy 
after rifampicin exposure (M Bester, MSc Thesis, 2009). To further investigate these findings, the 
expression profiles of genes involved in different pathways of ATP production were studied in M. 
tuberculosis isolates from different genetic backgrounds which displayed different level of rifampicin 
resistance. These results suggest that the energy requirements of M. tuberculosis adapts with the 
acquisition of additional drug resistance, with more energy metabolism genes being up-regulated in 
the mono-rifampicin resistant isolates when compared to MDR isolates. Secondly, MDR isolates with 
high rifampicin MICs also displayed an overall increase in the expression of energy metabolism genes 
when compared to the MDR isolates displaying low rifampicin MICs. This suggests that isolates with 
high rifampicin MICs have a higher energy requirement and therefore have adapted their 
transcriptional response to increase energy production. These findings together with the observation 





whereby M. tuberculosis regulates the intra-cellular concentration of rifampicin. We propose that 
increased energy produced upon rifampicin exposure will fuel efflux systems, resulting in decreased 
intra-cellular concentration of rifampicin. In contrast, inhibition of ATP synthesis (by TMC207) will 
deplete efflux and transporter systems from their energy requirements resulting in the accumulation of 
anti-TB drugs within the bacilli. The high intracellular concentration will lead to more efficient 
binding of the drugs to their targets leading to cell death. 
 
To further investigate mechanisms responsible for defining the level of rifampicin resistance, in vitro 
rifampicin resistant mutants which displayed different levels of rifampicin resistance (despite having 
identical rpoB mutations) were generated and sequenced. Analysis of these clones showed that the 
level of rifampicin resistance varied significantly amongst clones that shared identical rpoB 
mutations. Whole genome sequencing and bioinformatics analysis of two in vitro Ser531Leu mutants 
with varying rifampicin resistance levels showed that minor genetic changes are acquired with 
increased rifampicin resistance. 
 
In a separate experiment we showed using whole genome sequencing that MDR isolates presumed to 
be identical (shared identical RFLP fingerprints and drug resistance conferring mutations) were 
genetically distinct. This questions the use of RFLP methods to define epidemiological relationships 
between M. tuberculosis isolates (142). Furthermore, whole genome sequencing results suggest that 
strains from different clades employs distinct strategies to modulate rifampicin resistance levels.  
 
Although whole genome sequencing has proved to be a useful technique in unravelling the evolution 
of drug resistance (40, 142), this study also highlighted the importance of meticulous study design as 
we were not able to clearly define mechanisms beyond cell wall and lipid metabolism. Despite this 
limitation, this is a general theme seen in other studies investigating the physiology of drug resistance 
and therefore we believe that the structure of the cell wall plays a critical role in the transport of 
molecules in and out of the cell. To identify more detailed mechanisms, it would be essential to 
redesign our study to analyse single clones. Preliminary data from our group suggests that clinical 
isolates reflect a spectrum of different phenotypes with respect to the level of rifampicin resistance. In 
that ongoing study it has been shown that analysis of single colony forming units allowed the 
identification of clones with definitive levels of resistance. Analysis of these clones with whole 
genome sequencing is expected to provide novel insight into the mechanisms of defining the level of 
resistance without the complicating factors of mixed populations, which would not be detected by 
current whole genome sequencing techniques. This is in line as proposed by Ford and colleagues that 






In summary this was the first study to investigate the role of compensatory rpoC mutations in an 
epidemiological context. This study highlights the importance of compensatory mechanisms in the 
spread of M. tuberculosis isolates. This was the first study to sequence the whole genomes of clinical 
and in vitro rifampicin resistant M. tuberculosis isolates displaying varying levels of rifampicin 
resistance. Together with our findings of increased expression of energy metabolism genes after 
rifampicin exposure, these results indicates that rifampicin resistance is more complex than previously 
envisaged as M. tuberculosis uses both genetic and regulatory mechanisms to define the level of 
rifampicin resistance. The influence of genetic variants on the transcriptome (and vice versa) is 
however largely unknown. Understanding the physiology of M. tuberculosis in response to rifampicin 
exposure may aid in the development of drugs to improve the efficacy the current anti-TB drugs, such 
































1. Determine if the ATP synthase operon are encoded by a single polycistronic DNA. This could be 
done by PCR amplification of intragenic regions. 
2. Determine if there are any internal promoters inside the coding region. This could be done by 
cloning the intragenic region upstream of a reporter gene and then measuring expression of the 
reporter in M. smegmatis. 
3. Whole genome sequencing analysis from single colonies displaying variable rifampicin resistance 
phenotypes. This will be done single colony forming units reflecting the extreme MIC‟s from 5 
isolates which will be selected based on: a) isolates having the same rpoB mutation but different 
genetic backgrounds, and b) isolates having different rpoB mutations. 
4. Whole genome sequencing analysis of the MDR isolates investigated in this study will be repeated 
by including a closely related susceptible "progenitor" isolate, as well as using different reference 
genomes for alignment and mapping. 
5. Identify genetic variants resulting in increased resistance in isolates harbouring rpoB mutations 
which are regarded to display lower rifampicin resistance levels. For this single colonies will be 
selected from clinical isolates displaying lower rifampicin resistance levels (MIC ≤ 10 µg/ml) 
using the Luria Delbrück Fluctuation assay and a rifampicin selection concentration in increments 
of 10x above the isolates‟ rifampicin MIC. Whole genome sequencing and RNA sequencing will 
be done to identify mechanisms involved in increased rifampicin resistance. 
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BUFFERS AND SOLUTIONS 
Culture media: 
ADC mycobacterial liquid culturing media supplement: 
25 g Bovine serium albumin (BSA) Fraction V; 10 g glucose; 0.75 ml catalase. The supplement was 
prepared in ddH2O (500 ml), sterilised through a 0.22µm filtration unit and stored at 4°C.  
 
Middlebrook 7H9 liquid medium: 
4.7 g 7H9 medium; 2 ml glycerol; 0.5 ml polysorbate (Tween80). The broth was prepared in ddH2O 
(900 ml) and autoclaved for 15 min at 121°C. 
 
Middlebrook 7H10 solid medium: 
19 g 7H10 medium; 5 ml glycerol. The solid media was prepared in ddH2O (900 ml) and autoclaved 




5% sodium glutamate, 50 mM Tris-HCl (pH 7.4), 25 mM EDTA 
 
Proteinase K: 
5% sodium dodecyl sulphate, 100nM Tris-HCl (pH 7.8), 50 mM EDTA 
 
TE buffer: 




80 mg Rifampicin (Sigma); 10 % Dimethyl sulfoxide (DMSO) 
 
Gel electrophoresis: 
10 X TBE Buffer (pH 8.3): 
108 g 0.45M Tris; 55 g 0.44M boric acid; 7.4 g 10mM EDTA in 1 L dH2O 
 
Loading dye: 





TABLES AND FIGURES 
 
Table A1: Beijing in vitro mutants' genotypes for rpoB, malQ and TB16.3  
Progenitor Mutant name rpoB malQ TB16.3 
1 Pre-Rif culture WT WT Gly101Gly 
 
K636.18 His526Asp WT WT 
 
K636.22 His526Asp WT Gly101Gly 
 
K636.23 Ser531Trp WT WT 
2 Pre-Rif culture WT WT WT 
 
K636.21 His526Tyr WT WT 
 
K636.26 Ser522Leu WT WT 
12 Pre-Rif culture WT WT Gly101Gly 
 
K636.13 Ser522Trp WT Gly101Gly 
 
K636.54 H526R WT Gly101Gly 
21 Pre-Rif culture WT WT WT 
 
K636.30 Ser522Trp WT WT 
 
K636.38 His526Arg WT WT 
25 Pre-Rif culture WT WT WT 
 
K636.4 His526Arg WT WT 
 
K636.5 His526Arg WT WT 
 
K636.6 His526Arg WT WT 
 
K636.7 His526Tyr WT WT 
 
K636.8 His526His/Pro/Asp/Tyr WT WT 
 
K636.9 Ser522Trp WT WT 
 
K636.24 His526Tyr WT WT 
 
K636.43 Ser531Trp WT WT 
26 Pre-Rif culture WT WT Gly101Gly 
 
K636.11 WT WT WT 
 
K636.12 His526Asp WT WT 
 
K636.46 His526Asp WT WT 
 
K636.52 His526Asp WT WT 
 
K636.53 His526Asp WT WT 
27 Pre-Rif culture WT WT WT 
 
K636.15 His526Asp WT WT 
 
K636.20 His526Asp WT WT 
28 Pre-Rif culture WT WT Gly101Gly 
 
K636.42 His526Asp WT WT 
29 Pre-Rif culture WT WT Gly101Gly 
 
K636.17 His526Tyr WT WT 
 
K636.28 His526Arg WT WT 
 
K636.29 His526Arg WT WT 
 
K636.51 His526His/Arg WT WT 
30 Pre-Rif culture WT WT Gly101Gly +WT 
 





33 Pre-Rif culture WT WT Gly101Gly 
 
K636.25 His526Asp WT Gly101Gly 
36 Pre-Rif culture WT WT WT 
 
K636.1 (N36S1) Ser531Leu WT Gly101Gly 
37 Pre-Rif culture WT WT Gly101Gly +WT 
 
K636.2 (N37S1) Ser531Leu Val407Val Gly101Gly 
 
K636.10 WT WT Gly101Gly 
 
K636.44 Ser531Leu Val407Val Gly101Gly 
 
K636.47 His526Asp   Gly101Gly 
38 Pre-Rif culture WT WT Gly101Gly 
 
K636.45 Ser531Leu WT Gly101Gly 
39 Pre-Rif culture WT WT Gly101Gly +WT 
 
K636.16 His526Tyr WT Gly101Gly 
 
K636.40 His526Tyr WT Gly101Gly 
 
K636.50 His526Asp WT WT 
40 Pre-Rif culture WT WT WT 
 
K636.49 Ser531Leu WT Gly101Gly 
41 Pre-Rif culture WT WT Gly101Gly 
 
K636.32 His526Asp WT WT 
 
K636.39 Ser522Leu WT Gly101Gly 
42 Pre-Rif culture WT WT Gly101Gly +WT 
 
K636.3 Ser531Leu WT Gly101Gly 
 
K636.19 His526Arg WT Gly101Gly 
 
K636.37 His526Asp + Ser531Trp WT Gly101Gly +WT 
 
K636.48 Ser531Leu WT Gly101Gly 
43 Pre-Rif culture WT WT WT 
 
K636.33 Ser531Trp WT Gly101Gly 
 
K636.41 His526Asp WT Gly101Gly 
44 Pre-Rif culture WT WT Gly101Gly +WT 
 
K636.14 Ser522Trp WT WT 
 
K636.27 His526Tyr WT WT 
 
K636.34 His526Arg+ Ser531Trp WT WT 
 
K636.35 His526Tyr WT WT 
 





























1 His526Tyr 26 Ser522Leu 51 His526Arg 76 His526Tyr 
2 Ser522Trp 27 His526Tyr 52 Ser531Leu 77 His526Tyr 
3 His526Tyr 28 His526Arg 53 Ser522Trp 78 His526Asp 
4 His526Asp 29 Ser522Trp 54 Ser531Leu 79 His526Arg 
5 His526Tyr 30 Ser531Leu 55 His526Tyr 80 His526Tyr 
6 His526Tyr 31 His526Arg 56 His526Asp 81 Ser531Trp 
7 His526Tyr 32 His526Asp 57 Ser522Leu 82 His526Arg 
8 His526Tyr 34 His526Arg 58 His526Arg 83 His526Arg 
9 Ser522Trp 35 His526Asp 59 Ser522Leu 84 His526Arg 
10 His526Tyr 36 His526Arg 60 Ser531Leu 85 His526Arg 
11 Ser531Trp 37 Ser531Trp 62 His526Asp 86 His526Arg 
12 His526Tyr 38 His526Asp 63 His526Arg 87 His526Tyr 
13 Ser522Leu 39 Ser522Trp 64 His526Asp 88 Ser522Trp 
14 Asp516Val 40 Ser531Leu 65 His526Asp 89 Ser522Trp 
16 His526Arg 41 His526Arg 66 Ser531Leu 90 His526Arg 
17 Ser531Leu 42 Ser522Trp 67 Ser531Leu 91 His526Tyr 
18 Ser522Leu 43 Ser531Trp 68 His526Tyr 92 His526Tyr 
19 His526Arg 44 His526Tyr 69 His526Asp 93 His526Arg 
20 His526Asp 45 His526Arg 70 His526Arg 94 His526Tyr 
21 His526Tyr 46 His526Tyr 71 His526Arg 95 His526Tyr 
22 His526Asp 47 His526Tyr 72 Ser522Trp 96 His526Pro 
23 His526Arg 48 His526Tyr 73 His526Asp 97 His526Asp 
24 Ser522Trp 49 His526Tyr 74 His526Tyr 
  25 His526Asp 50 His526Asp 75 Ser531Leu 















Table A3: Distribution of SNPs in rpoC in clustered and unique RFLP types 
RFLP clustering rpoB mutation 
rpoC 
mutation 




Clustered 531TTG D485Y BEIJING 
Non-atypical 
Beijing MDR 2 
Clustered 531TTG G332R LCC 
Non-atypical 
Beijing MDR 1 









Beijing Pre-XDR 1 
Clustered 531TTG V483A BEIJING Atypical Beijing Pre-XDR 1 
Clustered 531TTG V483G BEIJING Atypical Beijing XDR 18 
Clustered 531TTG V483G BEIJING Atypical Beijing Pre-XDR 5 
Clustered 531TTG V483G BEIJING Atypical Beijing MDR 4 
Clustered 531TTG V483G BEIJING 
Non-atypical 
Beijing MDR 1 





Clustered 531TTG V483G T 
Non-atypical 
Beijing XDR 1 
Clustered 531TTG V483G T 
Non-atypical 
Beijing MDR 1 
Clustered 531TTG A542A LAM 
Non-atypical 
Beijing MDR 10 
Clustered 531TTG A542A LAM 
Non-atypical 
Beijing Pre-XDR 2 





Clustered 531TTG A542A LAM 
Non-atypical 
Beijing XDR 1 
Clustered 531TTG A542A LCC 
Non-atypical 
Beijing MDR 1 
Clustered 531TTG Wild-type BEIJING 
Non-atypical 
Beijing MDR 12 
Clustered 531TTG Wild-type LCC 
Non-atypical 
Beijing XDR 6 
Clustered 531TTG Wild-type BEIJING 
Non-atypical 
Beijing Pre-XDR 5 
Clustered 531TTG Wild-type LCC 
Non-atypical 
Beijing MDR 5 
Clustered 531TTG Wild-type BEIJING Atypical Beijing MDR 3 
Clustered 531TTG Wild-type BEIJING Atypical Beijing XDR 1 
Clustered 531TTG Wild-type BEIJING 
Non-atypical 
Beijing XDR 1 
Clustered 531TTG Wild-type EAI Unknown 
Rifampicin mono-
resistant 1 
Clustered 531TTG Unknown LCC 
Non-atypical 
Beijing XDR 2 
Clustered 511CCG V483G BEIJING Atypical Beijing MDR 1 
Clustered 511CCG Wild-type LCC 
Non-atypical 
Beijing MDR 1 
Clustered 516GTC V483G BEIJING Atypical Beijing Pre-XDR 1 
Clustered 516GTC Wild-type BEIJING Atypical Beijing XDR 10 
Clustered 516GTC Wild-type BEIJING Atypical Beijing Pre-XDR 4 
Clustered 516GTC Wild-type BEIJING Atypical Beijing MDR 2 
Clustered 516GTC Wild-type LCC 
Non-atypical 
Beijing XDR 1 
Clustered 516TAC Wild-type BEIJING Atypical Beijing Pre-XDR 1 
Clustered 516TAC Wild-type LCC 
Non-atypical 
Beijing Pre-XDR 1 
Clustered 516TAC Wild-type LCC 
Non-atypical 





RFLP clustering rpoB mutation 
rpoC 
mutation 




Clustered 526CGC Wild-type BEIJING 
Non-atypical 
Beijing MDR 1 





Clustered 526GAC Wild-type BEIJING 
Non-atypical 
Beijing Pre-XDR 1 
Clustered 526TAC Wild-type BEIJING Atypical Beijing 
Rifampicin mono-
resistant 1 
Clustered 526TAC Wild-type BEIJING Atypical Beijing MDR 1 
Clustered 526TAC Wild-type BEIJING 
Non-atypical 
Beijing MDR 1 
Clustered 526TAC Wild-type BEIJING 
Non-atypical 
Beijing Pre-XDR 1 
Clustered 526TAC Wild-type LCC 
Non-atypical 
Beijing MDR 1 
Clustered 531CAG Wild-type BEIJING 
Non-atypical 
Beijing MDR 1 
Clustered 531TTC A542A LAM 
Non-atypical 
Beijing MDR 1 
Clustered 533CCG Wild-type BEIJING 
Non-atypical 
Beijing Pre-XDR 1 
Clustered 533CCG Wild-type BEIJING 
Non-atypical 
Beijing MDR 1 





Clustered Wild-type A542A LAM 
Non-atypical 
Beijing XDR 2 










Clustered Wild-type Wild-type LCC 
Non-atypical 
Beijing Poly-resistant 6 
Clustered Wild-type Wild-type BEIJING Atypical Beijing Drug-sensitive 5 
Clustered Wild-type Wild-type LCC 
Non-atypical 
Beijing Drug-sensitive 5 





Clustered Wild-type Wild-type BEIJING 
Non-atypical 
Beijing Poly-resistant 1 
Clustered Wild-type Wild-type BEIJING Unknown Pre-XDR 1 
Clustered Wild-type Wild-type LAM 
Non-atypical 
Beijing Poly-resistant 1 
Clustered 531TTG D485Y BEIJING 
Non-atypical 
Beijing Pre-XDR 1 
Clustered 531TTG D485Y BEIJING 
Non-atypical 
Beijing MDR 1 
Clustered 531TTG F452C LCC 
Non-atypical 
Beijing Pre-XDR 1 
Clustered 531TTG H525Q LCC 
Non-atypical 
Beijing MDR 1 
Clustered 531TTG V483G T 
Non-atypical 
Beijing Pre-XDR 6 
Clustered 531TTG V483G T 
Non-atypical 
Beijing MDR 1 
Clustered Unknown/mix A542A LAM 
Non-atypical 
Beijing Drug-sensitive 7 
Clustered Unknown/mix A542A LAM 
Non-atypical 
Beijing MDR 3 
Clustered Unknown/mix A542A LAM 
Non-atypical 
Beijing Pre-XDR 2 
Clustered Unknown/mix Wild-type LCC 
Non-atypical 





RFLP clustering rpoB mutation 
rpoC 
mutation 




Clustered Unknown/mix Wild-type BEIJING 
Non-atypical 
Beijing Drug-sensitive 19 
Clustered Unknown/mix Wild-type LCC 
Non-atypical 
Beijing MDR 8 
Clustered Unknown/mix Wild-type BEIJING 
Non-atypical 
Beijing MDR 3 
Clustered Unknown/mix Wild-type LCC 
Non-atypical 
Beijing Pre-XDR 2 
Clustered Unknown/mix Wild-type BEIJING 
Non-atypical 
Beijing Pre-XDR 1 
Clustered Unknown/mix Wild-type BEIJING Unknown 
Isoniazid mono-
resistant 1 
Clustered Unknown/mix Wild-type BEIJING Unknown MDR 1 
Clustered Unknown/mix Wild-type LCC 
Non-atypical 
Beijing Poly-resistant 1 





Clustered Unknown/mix Wild-type unknown 
Non-atypical 
Beijing Drug-sensitive 1 
Clustered Unknown/mix Wild-type unknown 
Non-atypical 
Beijing Pre-XDR 1 









Beijing Pre-XDR 1 
Non-clustered 531TTG V483G BEIJING Atypical Beijing MDR 1 
Non-clustered 531TTG A542A LAM 
Non-atypical 
Beijing MDR 3 





Non-clustered 531TTG A542A LAM 
Non-atypical 
Beijing Pre-XDR 2 
Non-clustered 531TTG Wild-type BEIJING 
Non-atypical 
Beijing MDR 3 
Non-clustered 531TTG Wild-type HAARLEM 
Non-atypical 
Beijing XDR 1 





Non-clustered 531TTG Wild-type T 
Non-atypical 
Beijing MDR 1 





Non-clustered 511CCG Wild-type unknown 
Non-atypical 
Beijing MDR 1 
Non-clustered 516TAC Wild-type BEIJING Atypical Beijing XDR 1 
Non-clustered 526CGC Wild-type unknown 
Non-atypical 
Beijing MDR 1 





Non-clustered 526TAC Wild-type HAARLEM 
Non-atypical 
Beijing XDR 1 


































RFLP clustering rpoB mutation 
rpoC 
mutation 









Non-clustered Wild-type Wild-type LCC Unknown 
Isoniazid mono-
resistant 1 
Non-clustered 531TTG Q523E F28 
Non-atypical 
Beijing MDR 1 
Non-clustered 531TTG V483G BEIJING Atypical Beijing Pre-XDR 1 
Non-clustered 531TTG V483G T 
Non-atypical 
Beijing XDR 1 
Non-clustered Unknown/mix A542A LAM 
Non-atypical 
Beijing Drug-sensitive 4 
Non-clustered Unknown/mix A542A LAM 
Non-atypical 
Beijing MDR 3 
Non-clustered Unknown/mix A542A F26 
Non-atypical 
Beijing MDR 1 
Non-clustered Unknown/mix A542A unknown 
Non-atypical 
Beijing MDR 1 
Non-clustered Unknown/mix Wild-type BEIJING 
Non-atypical 
Beijing Drug-sensitive 2 
Non-clustered Unknown/mix Wild-type unknown 
Non-atypical 
Beijing MDR 2 
Non-clustered Unknown/mix Wild-type BEIJING Atypical Beijing XDR 1 
Non-clustered Unknown/mix Wild-type F28 
Non-atypical 
Beijing MDR 1 
Non-clustered Unknown/mix Wild-type T 
Non-atypical 
Beijing MDR 1 
Non-clustered Unknown/mix Wild-type unknown 
Non-atypical 
Beijing Pre-XDR 1 
Unknown 531TTG V483G BEIJING Atypical Beijing Pre-XDR 1 
Unknown 531TTG V483G T 
Non-atypical 
Beijing MDR 1 
Unknown 531TTG A542A LAM 
Non-atypical 
Beijing XDR 1 
Unknown 531TTG A542A unknown 
Non-atypical 
Beijing MDR 1 





Unknown Wild-type Wild-type BEIJING Unknown 
Rifampicin mono-
resistant 6 















Unknown Wild-type Wild-type unknown 
Non-atypical 
Beijing Pre-XDR 1 





A542A BEIJING Unknown MDR 1 
Unknown 531TTG V483G LAM 
Non-atypical 
Beijing Pre-XDR 1 
Unknown 531TTG V483G LCC 
Non-atypical 
Beijing MDR 1 
Unknown Unknown/mix A542A unknown 
Non-atypical 
Beijing MDR 2 










Unknown Unknown/mix Wild-type unknown 
Non-atypical 





RFLP clustering rpoB mutation 
rpoC 
mutation 




Unknown Unknown/mix Wild-type BEIJING Unknown 
Rifampicin mono-
resistant 2 
Unknown Unknown/mix Wild-type BEIJING Unknown MDR 1 
Unknown Unknown/mix Wild-type BEIJING Unknown 
Isoniazid mono-
resistant 1 
Unknown Unknown/mix Wild-type CAS 
Non-atypical 
Beijing Pre-XDR 1 
Unknown Unknown/mix Wild-type LCC 
Non-atypical 
Beijing MDR 1 
Unknown Unknown/mix Wild-type unknown 
Non-atypical 
Beijing Pre-XDR 1 







Figure A1: BoxWhisper plot for quality scores across all bases 
Legend to Figure A1: 
The blue line within the yellow boxes represents the median quality value for the respective bases. 
This graph indicates good quality calls for the first 75 base pairs, where it starts to drop toward the 







Figure A2: Distrubtion of quality scores across all sequences in the library 
Legend to Figure A2: 
The mean quality (Phred) score is calculated across all bases in the library. Only a small subset of 




Figure A3: Sequence content across all bases in the library 
Legend to Figure A3: 
This figure indicates higher proportion of G and C bases in this library, which is expected of a M. 






Figure A4: The mean percentage of the GC content across all bases 
Legend to Figure A4: 
The horizontal plot across the graph indicates minimal change in the average GC content across all 
bases. It also confirms the expected high GC content of M. tuberculosis which is above 60% 
 
 
Figure A5: The mean distribution of the percentage GC content across all sequences 
Legend to Figure A5: 
A normal distribution of the GC content is observed with the central peak corresponding to the overall 








Figure A6: Sequence duplication levels in the library sequenced 
Legend to Figure A6: 
This plot indicates that a high percentage of duplicate sequences are present. This however might be 
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